



09/ 832929

Co/C\$

PATENT  
Customer No. 22,852  
Attorney Docket No. 6832.0013

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re U.S. Patent No.: 6,926,898 )  
Inventors: )  
Craig A. Rosen and William A. Haseltine )  
Issue Date.: August 9, 2005 )  
For: ALBUMIN FUSION PROTEINS )

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**REQUEST FOR CERTIFICATE OF CORRECTION**

Pursuant to 35 U.S.C. §§ 254 and 255, and 37 C.F.R. §§ 1.322 and 1.323, this is a request for a Certificate of Correction in the above-identified patent. Some of the mistakes identified in the appended Form occurred through the fault of the Patent Office, as clearly disclosed by the records of the application which matured into this patent.

For example, the priority claims to Provisional Application Nos. 60/256,931, filed December 21, 2000; 60/199,384, filed April 25, 2000; and 60/229,358, filed April 12, 2000, were deleted in an Amendment filed February 4, 2004, and a Corrected Filing Receipt reflecting the change was mailed by the PTO on February 13, 2004. However, the issued patent was printed with the priority claims in the title page under item (60).

Furthermore, the omitted U.S. Patent Documents under item (56) (References Cited) in the title page, were cited by Applicants in an Information Disclosure Statement

JAN 04 2006

filed April 5, 2004, and the Office returned the initialed Form PTO 1449 with the Supplemental Notice of Allowance mailed June 29, 2004.

The omitted OTHER PUBLICATIONS under item (56) (References Cited) in the title page, were also cited by Applicants in the Information Disclosure Statement filed April 5, 2004, and the Office returned the initialed Form PTO 1449 by facsimile on July 23, 2004.

The issued patent was printed without the Examiner's Amendment to the specification mailed March 3, 2005, with the Supplemental Notice of Allowance. The attached Certificate of Correction amends the specification according to the Examiner's Amendment.

Furthermore, the issued patent reflects the original Sequence Listing filed rather than the Substitute Sequence Listing submitted on August 20, 2004. The Sequence Listing in the attached Certificate of Correction is identical to the Substitute Sequence Listing filed on August 20, 2004, and is also identical to the computer readable copy of the Substitute Sequence Listing also submitted on August 20, 2004. Thus, the correction contains no new matter.

Other mistakes identified in the appended Form are of a clerical or typographical nature, or of minor character, and resulted from an error made in good faith by patentees. A check in the amount of \$100 (the fee set forth in 37 C.F.R. § 1.20(a)) is attached. Should a check not be appended or should any additional fees be needed, authorization is hereby given to charge any fees due in connection with the filing of this request to Deposit Account No. 06-0916.

JAN 04 2005

Two (2) copies of PTO Form 1050 are appended. The complete Certificate of Correction involves thirty-five (35) pages. Issuance of the Certificate of Correction containing the correction is earnestly requested.

Please charge any required fees not included herewith to our deposit account 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

Dated: December 23, 2005

By: Charles E Van Horn  
Charles E. Van Horn  
Reg. No. 40,266

JAN 04 2006

**UNITED STATES PATENT AND TRADEMARK OFFICE**  
**CERTIFICATE OF CORRECTION**

PATENT NO. 6,926,898

Page 1 of 35

APPLICATION NO.: 09/832,929

ISSUE DATE: August 9, 2005

INVENTOR(S): Craig A. Rosen and William A. Haseltine

It is hereby certified that an error or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Under item (60) (Related U.S. Application Data) of the title page, delete the text beginning with "Provisional application No. 60/256,931" to and ending "provisional application No. 60/229,358, filed on Apr. 12, 2000."

Under item (56) (References Cited) of the title page and under U.S. PATENT DOCUMENTS beginning on page 1, insert:

--	2003-0022308 A1	1/2003	Fleer et al.
	2003-0036170 A1	2/2003	Fleer et al.
	2003-0036171 A1	2/2003	Fleer et al.
	2003-0036172 A1	2/2003	Fleer et al.
	2003-0054554 A1	3/2003	Becquart et al.
	2003-0082747 A1	5/2003	Fleer et al.
	2003-0104578 A1	10/2001	Ballance
	2004-0010134 A1	4/2001	Rosen et al.
	09/832,501	4/2001	Ballance et al.
	09/833,041	4/2001	Rosen et al.
	09/833,111	4/2001	Rosen et al.
	09/833,117	4/2001	Rosen et al.
	09/833,118	4/2001	Rosen et al.
	10/702,536	11/2003	Fleer et al.
	10/702,636	11/2003	Fleer et al. --

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,  
Garrett & Dunner, L.L.P.  
901 New York Avenue, N.W.  
Washington, D.C. 20001-4413

JAN 04 2006

Under item (56) (References Cited) of the title page and under OTHER PUBLICATIONS beginning on page 1, insert:

- Larsson, M., et al., "Role of Annexins in Endocytosis of Antigens in Immature Human Dendritic Cells," *Immunology* 92:501-511 (1997).
- Latta, M. et al., "Synthesis and Purification of Mature Human Serum Albumin From *E. Coli*," *Bio/Technology* 5:1309-1314 (1987).
- Latta, M., et al., "Tryptophan Promoter Derivatives on Multicopy Plasmids: A Comparative Analysis of Expression Potentials in *Escherichia coli*," *DNA and Cell Biology* 9:129-137 (1990).
- Lawn, R.M., et al., "The Sequence of Human Serum Albumin cDNA and its Expression in *E. coli*," *Nucleic Acids Research* 9:6103-6113 (1981).
- Le Bras, M., et al., "Epidemiologie et Clinique des Maladies Tropicales D'importation," *La Revue de Medicine Interne* 13:205-210 (1992), with English translation.
- Leblois, H., et al., "Stable Transduction of Actively Dividing Cells via a Novel Adenoviral/Episomal Vector," *Molecular Therapy* 1:314-322 (2000).
- Lee, C-H., et al., "Sodium Pertechnetate Tc99m Antral Scan in the Diagnosis of Retained Gastric Antrum," *Arch. Surg.* 119: 309-311 (1984).
- Lee, C-L., et al., "Preparation and Characterization of Polyethylene-Glycol-Modified Salmon Calcitonins," *Pharmaceutical Development and Technology*, 4(2): 269-275 (1999).
- Lee, W-C., et al., "Identification and Characterization of a Nuclear Localization Sequence-Binding Protein in Yeast," *Proc. Natl. Acad. Sci. USA* 86:8808-8812 (1989).
- Lee, Y-H., et al., "Comparison of Effective Renal Plasma Flow (ERPF) and Endogenous Creatinine Clearance (Ccr) in Evaluation of the Differential Kidney Function: An in Vivo Study," *Chin. Med. J. (Taipei)* 49:147-152 (1992).
- Lei, H-Y., et al., "An Antigen-specific Hypersensitivity Which Does Not Fit Into Traditional Classification of Hypersensitivity," *The Journal of Immunology* 143:432-438 (1989).
- Levitt, D., et al., "Toxicity of Perfluorinated Fatty-Acids for Human and Murine B Cell Lines," *Toxicology and Applied Pharmacology* 86:1-11 (1986).

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,  
Garrett & Dunner, L.L.P.  
901 New York Avenue, N.W.  
Washington, D.C. 20001-4413

JAN 04 2006

Lew D.B., et al., "Mitogenic Effect of Lysosomal Hydrolases on Bovine Tracheal Myocytes in Culture," *The Journal of Clinical Investigation* 88:1969-1975 (1991).

Lewis, C., et al., "Is Sexual Dysfunctoin in Hypertensive Women Uncommon or Understudied?" *American Jour of Hypertension*," 11:733-735 (1998). --

Under item (57) (ABSTRACT) of the title page, "disordrs" should read --disorders--.

In the Specification

Col. 143, line 26, delete "As exhibited in Table 2, most", and insert --Most--.

Col. 143, line 31, delete "Table 2".

In the Claims

Col. 340, line 40, delete "an".

Col. 340, line 47, delete "an".

In the Sequence Listing

Delete the Sequence Listing beginning in Col. 299, beginning with the text "<160> NUMBER OF SEQ ID NOS: 72" to and ending "<400> SEQUENCE: 72

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser  
1 5 10 15"

in Col. 340 and insert the following Sequence Listing:

<160> NUMBER OF SEQ ID NOS: 82

<210> 1

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> primer\_bind

<223> primer useful to clone human growth hormone cDNA

<400> 1

cccaagaatt cccttatcca ggc

23

<210> 2

<211> 33

<212> DNA

<213> Artificial Sequence

<220>

<221> primer\_bind

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,  
Garrett & Dunner, L.L.P.  
901 New York Avenue, N.W.  
Washington, D.C. 20001-4413

JAN 04 2006

<223> primer useful to clone human growth hormone cDNA

<400> 2  
gggaagctta gaagccacag gatccctcca cag 33

<210> 3  
<211> 16  
<212> DNA  
<213> Artificial Sequence  
<220>  
<221> misc\_structure  
<223> synthetic oligonucleotide used to join DNA fragments with non-cohesive ends.

<400> 3  
gataaagatt cccaac 16

<210> 4  
<211> 17  
<212> DNA  
<213> Artificial Sequence  
<220>  
<221> misc\_structure  
<223> synthetic oligonucleotide used to join DNA fragments with non-cohesive ends.

<400> 4  
aattgttggg aatcttt 17

<210> 5  
<211> 17  
<212> DNA  
<213> Artificial Sequence  
<220>  
<221> misc\_structure  
<223> synthetic oligonucleotide used to join DNA fragments with non-cohesive ends.

<400> 5  
ttaggcttat tccaac 17

<210> 6  
<211> 18  
<212> DNA  
<213> Artificial Sequence  
<220>  
<221> misc\_structure  
<223> synthetic oligonucleotide used to join DNA fragments with non-cohesive ends.

<400> 6  
aattgttggg aataagcc 18

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,  
Garrett & Dunner, L.L.P.  
901 New York Avenue, N.W.  
Washington, D.C. 20001-4413

JAN 04 2006

```

<210> 7
<211> 24
<212> PRT
<213> Artificial Sequence
<220>
<221> SITE
<222> 1)..(19)
<223> invertase leader sequence
<220>
<221> SITE
<222> 20)..(24)
<223> first 5 amino acids of mature human serum albumin

<400> 7
Met Leu Leu Gln Ala Phe Leu Phe Leu Leu Ala Gly Phe Ala Ala Lys
  1             5             10             15

Ile Ser Ala Asp Ala His Lys Ser
          20

<210> 8
<211> 21
<212> DNA
<213> Artificial Sequence
<220>
<221> misc_structure
<223> synthetic oligonucleotide used to join DNA fragments with non-cohesive
ends.

<400> 8
gagatgcaca cctgagtgag g                                21

<210> 9
<211> 27
<212> DNA
<213> Artificial Sequence
<220>
<221> misc_structure
<223> synthetic oligonucleotide used to join DNA fragments with non-cohesive
ends.

<400> 9
gatcctgtgg cttcgtatgca cacaaga                            27

<210> 10
<211> 24
<212> DNA
<213> Artificial Sequence
<220>
<221> misc_structure
<223> synthetic oligonucleotide used to join DNA fragments with non-cohesive
ends.

```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,  
Garrett & Dunner, L.L.P.  
901 New York Avenue, N.W.  
Washington, D.C. 20001-4413

JAN 04 2006

<400> 10	
ctcttggtgtg catcgaagcc acag	24
<210> 11	
<211> 30	
<212> DNA	
<213> Artificial Sequence	
<220>	
<221> misc_structure	
<223> synthetic oligonucleotide used to join DNA fragments with non-cohesive ends.	
<400> 11	
tgtggaagag cctcagaatt tattcccaac	30
<210> 12	
<211> 31	
<212> DNA	
<213> Artificial Sequence	
<220>	
<221> misc_structure	
<223> synthetic oligonucleotide used to join DNA fragments with non-cohesive ends.	
<400> 12	
aattgttggg aataaattct gaggtctttc c	31
<210> 13	
<211> 47	
<212> DNA	
<213> Artificial Sequence	
<220>	
<221> misc_structure	
<223> synthetic oligonucleotide used to join DNA fragments with non-cohesive ends.	
<400> 13	
ttaggcttag gtggcggtgg atccggcggt ggtggatctt toccaac	47
<210> 14	
<211> 48	
<212> DNA	
<213> Artificial Sequence	
<220>	
<221> misc_structure	
<223> synthetic oligonucleotide used to join DNA fragments with non-cohesive ends.	
<400> 14	
aattgttggg aaagatccac caccgccgga tccaccgcc cctaagcc	48

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,  
Garrett & Dunner, L.L.P.  
901 New York Avenue, N.W.  
Washington, D.C. 20001-4413

JAN 04 2006

```

<210> 15
<211> 62
<212> DNA
<213> Artificial Sequence
<220>
<221> misc_structure
<223> synthetic oligonucleotide used to join DNA
fragments with non-cohesive ends.

<400> 15
ttaggcttag gcggtggtgg atctggtggc ggcgatctg gtggcggtgg atccttccca 60
ac 62

<210> 16
<211> 63
<212> DNA
<213> Artificial Sequence
<220>
<221> misc_structure
<223> synthetic oligonucleotide used to join DNA
fragments with non-cohesive ends.

<400> 16
aattgttggg aaggatccac cgccaccaga tccgccgcca ccagatccac caccgcctaa 60
gcc 63

<210> 17
<211> 1782
<212> DNA
<213> Homo sapiens
<220>
<221> CDS
<222> (1)..(1755)

<400> 17
gat gca cac aag agt gag gtt gct cat cgg ttt aaa gat ttg gga gaa 48
Asp Ala His Lys Ser Glu Val Ala His Arg Phe Lys Asp Leu Gly Glu
1 5 10 15

gaa aat ttc aaa gcc ttg gtg ttg att gcc ttt gct cag tat ctt cag 96
Glu Asn Phe Lys Ala Leu Val Leu Ile Ala Phe Ala Gln Tyr Leu Gln
20 25 30

cag tgt cca ttt gaa gat cat gta aaa tta gtg aat gaa gta act gaa 144
Gln Cys Pro Phe Glu Asp His Val Lys Leu Val Asn Glu Val Thr Glu
35 40 45

ttt gca aaa aca tgt gtt gct gat gag tca gct gaa aat tgt gac aaa 192
Phe Ala Lys Thr Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys
50 55 60

```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,  
Garrett & Dunner, L.L.P.  
901 New York Avenue, N.W.  
Washington, D.C. 20001-4413

JAN 04 2006

tca ctt cat acc ctt ttt gga gac aaa tta tgc aca gtt gca act ctt	240
Ser Leu His Thr Leu Phe Gly Asp Lys Leu Cys Thr Val Ala Thr Leu	
65 70 75 80	
cgt gaa acc tat ggt gaa atg gct gac tgc tgt gca aaa caa gaa cct	288
Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys Cys Ala Lys Gln Glu Pro	
85 90 95	
gag aga aat gaa tgc ttc ttg caa cac aaa gat gac aac cca aac ctc	336
Glu Arg Asn Glu Cys Phe Leu Gln His Lys Asp Asp Asn Pro Asn Leu	
100 105 110	
ccc cga ttg gtg aga cca gag gtt gat gtg atg tgc act gct ttt cat	384
Pro Arg Leu Val Arg Pro Glu Val Asp Val Met Cys Thr Ala Phe His	
115 120 125	
gac aat gaa gag aca ttt ttg aaa aaa tac tta tat gaa att gcc aga	432
Asp Asn Glu Glu Thr Phe Leu Lys Lys Tyr Leu Tyr Glu Ile Ala Arg	
130 135 140	
aga cat cct tac ttt tat gcc ccg gaa ctc ctt ttc ttt gct aaa agg	480
Arg His Pro Tyr Phe Tyr Ala Pro Glu Leu Leu Phe Phe Ala Lys Arg	
145 150 155 160	
tat aaa gct gct ttt aca gaa tgt tgc caa gct gct gat aaa gct gcc	528
Tyr Lys Ala Ala Phe Thr Glu Cys Cys Gln Ala Ala Asp Lys Ala Ala	
165 170 175	
tgc ctg ttg cca aag ctc gat gaa ctt cgg gat gaa ggg aag gct tcg	576
Cys Leu Leu Pro Lys Leu Asp Glu Leu Arg Asp Glu Gly Lys Ala Ser	
180 185 190	
tct gcc aaa cag aga ctc aaa tgt gcc agt ctc caa aaa ttt gga gaa	624
Ser Ala Lys Gln Arg Leu Lys Cys Ala Ser Leu Gln Lys Phe Gly Glu	
195 200 205	
aga gct ttc aaa gca tgg gca gtg gct cgc ctg agc cag aga ttt ccc	672
Arg Ala Phe Lys Ala Trp Ala Val Ala Arg Leu Ser Gln Arg Phe Pro	
210 215 220	
aaa gct gag ttt gca gaa gtt tcc aag tta gtg aca gat ctt acc aaa	720
Lys Ala Glu Phe Ala Glu Val Ser Lys Leu Val Thr Asp Leu Thr Lys	
225 230 235 240	
gtc cac acg gaa tgc tgc cat gga gat ctg ctt gaa tgt gct gat gac	768
Val His Thr Glu Cys Cys His Gly Asp Leu Leu Glu Cys Ala Asp Asp	
245 250 255	
agg gcg gac ctt gcc aag tat atc tgt gaa aat cag gat tcg atc tcc	816
Arg Ala Asp Leu Ala Lys Tyr Ile Cys Glu Asn Gln Asp Ser Ile Ser	
260 265 270	

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,  
Garrett & Dunner, L.L.P.  
901 New York Avenue, N.W.  
Washington, D.C. 20001-4413

JAN 04 2006

agt aaa ctg aag gaa tgc tgt gaa aaa cct ctg ttg gaa aaa tcc cac	864
Ser Lys Leu Lys Glu Cys Cys Glu Lys Pro Leu Leu Glu Lys Ser His	
275 280 285	
tgc att gcc gaa gtg gaa aat gat gag atg cct gct gac ttg cct tca	912
Cys Ile Ala Glu Val Glu Asn Asp Glu Met Pro Ala Asp Leu Pro Ser	
290 295 300	
tta gct gct gat ttt gtt gaa agt aag gat gtt tgc aaa aac tat gct	960
Leu Ala Ala Asp Phe Val Glu Ser Lys Asp Val Cys Lys Asn Tyr Ala	
305 310 315 320	
gag gca aag gat gtc ttc ctg ggc atg ttt ttg tat gaa tat gca aga	1008
Glu Ala Lys Asp Val Phe Leu Gly Met Phe Leu Tyr Glu Tyr Ala Arg	
325 330 335	
agg cat cct gat tac tct gtc gtg ctg ctg ctg aga ctt gcc aag aca	1056
Arg His Pro Asp Tyr Ser Val Val Leu Leu Leu Arg Leu Ala Lys Thr	
340 345 350	
tat gaa acc act cta gag aag tgc tgt gcc gct gca gat cct cat gaa	1104
Tyr Glu Thr Thr Leu Glu Lys Cys Cys Ala Ala Ala Asp Pro His Glu	
355 360 365	
tgc tat gcc aaa gtg ttc gat gaa ttt aaa cct ctt gtg gaa gag cct	1152
Cys Tyr Ala Lys Val Phe Asp Glu Phe Lys Pro Leu Val Glu Glu Pro	
370 375 380	
cag aat tta atc aaa caa aac tgt gag ctt ttt gag cag ctt gga gag	1200
Gln Asn Leu Ile Lys Gln Asn Cys Glu Leu Phe Glu Gln Leu Gly Glu	
385 390 395 400	
tac aaa ttc cag aat gcg cta tta gtt cgt tac acc aag aaa gta ccc	1248
Tyr Lys Phe Gln Asn Ala Leu Leu Val Arg Tyr Thr Lys Lys Val Pro	
405 410 415	
caa gtg tca act cca act ctt gta gag gtc tca aga aac cta gga aaa	1296
Gln Val Ser Thr Pro Thr Leu Val Glu Val Ser Arg Asn Leu Gly Lys	
420 425 430	
gtg ggc agc aaa tgt tgt aaa cat cct gaa gca aaa aga atg ccc tgt	1344
Val Gly Ser Lys Cys Cys Lys His Pro Glu Ala Lys Arg Met Pro Cys	
435 440 445	
gca gaa gac tat cta tcc gtg gtc ctg aac cag tta tgt gtg ttg cat	1392
Ala Glu Asp Tyr Leu Ser Val Val Leu Asn Gln Leu Cys Val Leu His	
450 455 460	
gag aaa acg cca gta agt gac aga gtc aca aaa tgc tgc aca gag tcc	1440
Glu Lys Thr Pro Val Ser Asp Arg Val Thr Lys Cys Cys Thr Glu Ser	
465 470 475 480	

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,  
Garrett & Dunner, L.L.P.  
901 New York Avenue, N.W.  
Washington, D.C. 20001-4413

JAN 04 2006

```

ttg gtg aac agg cga cca tgc ttt tca gct ctg gaa gtc gat gaa aca 1488
Leu Val Asn Arg Arg Pro Cys Phe Ser Ala Leu Glu Val Asp Glu Thr
485 490 495

tac gtt ccc aaa gag ttt aat gct gaa aca ttc acc ttc cat gca gat 1536
Tyr Val Pro Lys Glu Phe Asn Ala Glu Thr Phe Thr Phe His Ala Asp
500 505 510

ata tgc aca ctt tct gag aag gag aga caa atc aag aaa caa act gca 1584
Ile Cys Thr Leu Ser Glu Lys Glu Arg Gln Ile Lys Lys Gln Thr Ala
515 520 525

ctt gtt gag ctt gtg aaa cac aag ccc aag gca aca aaa gag caa ctg 1632
Leu Val Glu Leu Val Lys His Lys Pro Lys Ala Thr Lys Glu Gln Leu
530 535 540

aaa gct gtt atg gat gat ttc gca gct ttt gta gag aag tgc tgc aag 1680
Lys Ala Val Met Asp Asp Phe Ala Ala Phe Val Glu Lys Cys Cys Lys
545 550 555 560

gct gac gat aag gag acc tgc ttt gcc gag gag ggt aaa aaa ctt gtt 1728
Ala Asp Asp Lys Glu Thr Cys Phe Ala Glu Glu Gly Lys Lys Leu Val
565 570 575

gct gca agt caa gct gcc tta ggc tta taacatctac atttaaaagc atctcag 1782
Ala Ala Ser Gln Ala Ala Leu Gly Leu
580 585

<210> 18
<211> 585
<212> PRT
<213> Homo Sapiens

<400> 18
Asp Ala His Lys Ser Glu Val Ala His Arg Phe Lys Asp Leu Gly Glu
1 5 10 15
Glu Asn Phe Lys Ala Leu Val Leu Ile Ala Phe Ala Gln Tyr Leu Gln
20 25 30
Gln Cys Pro Phe Glu Asp His Val Lys Leu Val Asn Glu Val Thr Glu
35 40 45
Phe Ala Lys Thr Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys
50 55 60
Ser Leu His Thr Leu Phe Gly Asp Lys Leu Cys Thr Val Ala Thr Leu
65 70 75 80
Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys Cys Ala Lys Gln Glu Pro
85 90 95

```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,  
Garrett & Dunner, L.L.P.  
901 New York Avenue, N.W.  
Washington, D.C. 20001-4413

JAN 04 2006

Glu Arg Asn Glu Cys Phe Leu Gln His Lys Asp Asp Asn Pro Asn Leu	100	105	110
Pro Arg Leu Val Arg Pro Glu Val Asp Val Met Cys Thr Ala Phe His	115	120	125
Asp Asn Glu Glu Thr Phe Leu Lys Lys Tyr Leu Tyr Glu Ile Ala Arg	130	135	140
Arg His Pro Tyr Phe Tyr Ala Pro Glu Leu Leu Phe Phe Ala Lys Arg	145	150	155
Tyr Lys Ala Ala Phe Thr Glu Cys Cys Gln Ala Ala Asp Lys Ala Ala	165	170	175
Cys Leu Leu Pro Lys Leu Asp Glu Leu Arg Asp Glu Gly Lys Ala Ser	180	185	190
Ser Ala Lys Gln Arg Leu Lys Cys Ala Ser Leu Gln Lys Phe Gly Glu	195	200	205
Arg Ala Phe Lys Ala Trp Ala Val Ala Arg Leu Ser Gln Arg Phe Pro	210	215	220
Lys Ala Glu Phe Ala Glu Val Ser Lys Leu Val Thr Asp Leu Thr Lys	225	230	235
Val His Thr Glu Cys Cys His Gly Asp Leu Leu Glu Cys Ala Asp Asp	245	250	255
Arg Ala Asp Leu Ala Lys Tyr Ile Cys Glu Asn Gln Asp Ser Ile Ser	260	265	270
Ser Lys Leu Lys Glu Cys Cys Glu Lys Pro Leu Leu Glu Lys Ser His	275	280	285
Cys Ile Ala Glu Val Glu Asn Asp Glu Met Pro Ala Asp Leu Pro Ser	290	295	300
Leu Ala Ala Asp Phe Val Glu Ser Lys Asp Val Cys Lys Asn Tyr Ala	305	310	315
Glu Ala Lys Asp Val Phe Leu Gly Met Phe Leu Tyr Glu Tyr Ala Arg	325	330	335
Arg His Pro Asp Tyr Ser Val Val Leu Leu Leu Arg Leu Ala Lys Thr	340	345	350
Tyr Glu Thr Thr Leu Glu Lys Cys Cys Ala Ala Ala Asp Pro His Glu	355	360	365

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,  
Garrett & Dunner, L.L.P.  
901 New York Avenue, N.W.  
Washington, D.C. 20001-4413

JAN 04 2006

Cys Tyr Ala Lys Val Phe Asp Glu Phe Lys Pro Leu Val Glu Glu Pro  
 370 375 380  
 Gln Asn Leu Ile Lys Gln Asn Cys Glu Leu Phe Glu Gln Leu Gly Glu  
 385 390 395 400  
 Tyr Lys Phe Gln Asn Ala Leu Leu Val Arg Tyr Thr Lys Lys Val Pro  
 405 410 415  
 Gln Val Ser Thr Pro Thr Leu Val Glu Val Ser Arg Asn Leu Gly Lys  
 420 425 430  
 Val Gly Ser Lys Cys Cys Lys His Pro Glu Ala Lys Arg Met Pro Cys  
 435 440 445  
 Ala Glu Asp Tyr Leu Ser Val Val Leu Asn Gln Leu Cys Val Leu His  
 450 455 460  
 Glu Lys Thr Pro Val Ser Asp Arg Val Thr Lys Cys Cys Thr Glu Ser  
 465 470 475 480  
 Leu Val Asn Arg Arg Pro Cys Phe Ser Ala Leu Glu Val Asp Glu Thr  
 485 490 495  
 Tyr Val Pro Lys Glu Phe Asn Ala Glu Thr Phe Thr Phe His Ala Asp  
 500 505 510  
 Ile Cys Thr Leu Ser Glu Lys Glu Arg Gln Ile Lys Lys Gln Thr Ala  
 515 520 525  
 Leu Val Glu Leu Val Lys His Lys Pro Lys Ala Thr Lys Glu Gln Leu  
 530 535 540  
 Lys Ala Val Met Asp Asp Phe Ala Ala Phe Val Glu Lys Cys Cys Lys  
 545 550 555 560  
 Ala Asp Asp Lys Glu Thr Cys Phe Ala Glu Glu Gly Lys Lys Leu Val  
 565 570 575  
 Ala Ala Ser Gln Ala Ala Leu Gly Leu  
 580 585

<210> 19

<211> 58

<212> DNA

<213> Artificial Sequence

<220>

<221> primer\_bind

<223> primer used to generate XhoI and ClaI site in pPPC0006

<400> 19

gcctcgagaa aagagatgca cacaagagtg aggttgctca tcgatttaaa gatttggg 58

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,  
 Garrett & Dunner, L.L.P.  
 901 New York Avenue, N.W.  
 Washington, D.C. 20001-4413

JAN 04 2006

```

<210> 20
<211> 59
<212> DNA
<213> Artificial Sequence
<220>
<221> primer_bind
<223> primer used in generation XhoI and ClaI site in pPPC0006

<400> 20
aatcgatgag caacctcact cttgtgtgca tctcttttct cgaggctcct ggaataagc 59

<210> 21
<211> 24
<212> DNA
<213> Artificial Sequence
<220>
<221> primer_bind
<223> primer used in generation XhoI and ClaI site in pPPC0006

<400> 21
tacaaactta agagtccaat tagc 24

<210> 22
<211> 29
<212> DNA
<213> Artificial Sequence
<220>
<221> primer_bind
<223> primer used in generation XhoI and ClaI site in pPPC0006

<400> 22
cacttctcta gagtggtttc atatgtctt 29

<210> 23
<211> 60
<212> DNA
<213> Artificial Sequence
<220>
<221> Misc_Structure
<223> Synthetic oligonucleotide used to alter restriction sites in pPPC0007

<400> 23
aagctgcctt aggcttataa taaggcgcgc cggccggccg tttaaactaa gcttaattct 60

<210> 24
<211> 60
<212> DNA
<213> Artificial Sequence
<220>
<221> Misc_Structure
<223> Synthetic oligonucleotide used to alter restriction sites in pPPC0007

```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,  
Garrett & Dunner, L.L.P.  
901 New York Avenue, N.W.  
Washington, D.C. 20001-4413

JAN 04 2006

<400> 24  
 agaattaagc ttagtttaaa cggccggccg gcgcgcctta ttataagcct aaggcagctt 60  
  
 <210> 25  
 <211> 32  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <221> primer\_bind  
 <223> forward primer useful for generation of albumin fusion protein in which  
 the albumin moiety is N-terminal of the Therapeutic Protein  
 <220>  
 <221> misc feature  
 <222> (18)  
 <223> n equals a,t,g, or c  
 <220>  
 <221> misc feature  
 <222> (19)  
 <223> n equals a,t,g, or c  
 <220>  
 <221> misc feature  
 <222> (20)  
 <223> n equals a,t,g, or c  
 <220>  
 <221> misc feature  
 <222> (21)  
 <223> n equals a,t,g, or c  
 <220>  
 <221> misc feature  
 <222> (22)  
 <223> n equals a,t,g, or c  
 <220>  
 <221> misc feature  
 <222> (23)  
 <223> n equals a,t,g, or c  
 <220>  
 <221> misc feature  
 <222> (24)  
 <223> n equals a,t,g, or c  
 <220>  
 <221> misc feature  
 <222> (25)  
 <223> n equals a,t,g, or c  
 <220>  
 <221> misc feature  
 <222> (26)  
 <223> n equals a,t,g, or c  
 <220>  
 <221> misc feature  
 <222> (27)  
 <223> n equals a,t,g, or c  
 <220>

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,  
 Garrett & Dunner, L.L.P.  
 901 New York Avenue, N.W.  
 Washington, D.C. 20001-4413

JAN 04 2006

```

<221> misc feature
<222> (28)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (29)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (30)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (31)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (32)
<223> n equals a,t,g, or c

<400> 25
aagctgcctt aggcttannn nnnnnnnnnn nn

<210> 26
<211> 51
<212> DNA
<213> Artificial Sequence
<220>
<221> primer_bind
<223> reverse primer useful for generation of albumin fusion protein in which
the albumin moiety is N-terminal of the Therapeutic Protein
<220>
<221> misc feature
<222> (37)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (38)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (39)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (40)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (41)
<223> n equals a,t,g, or c
<220>

```

32

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,  
Garrett & Dunner, L.L.P.  
901 New York Avenue, N.W.  
Washington, D.C. 20001-4413

JAN 04 2006

```

<221> misc feature
<222> (42)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (43)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (44)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (45)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (46)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (47)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (48)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (49)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (50)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (51)
<223> n equals a,t,g, or c

<400> 26
gcgcgcgttt aaacggccgg ccggcgcgcc ttattannnn nnnnnnnnnn n

<210> 27
<211> 33
<212> DNA
<213> Artificial Sequence
<220>
<223> forward primer useful for generation of albumin fusion protein in which
the albumin moiety is c-terminal of the Therapeutic Protein
<220>
<221> misc feature

```

51

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,  
Garrett & Dunner, L.L.P.  
901 New York Avenue, N.W.  
Washington, D.C. 20001-4413

JAN 04 2006

<222> (19)  
 <223> n equals a,t,g, or c  
 <220>  
 <221> misc feature  
 <222> (20)  
 <223> n equals a,t,g, or c  
 <220>  
 <221> misc feature  
 <222> (21)  
 <223> n equals a,t,g, or c  
 <220>  
 <221> misc feature  
 <222> (22)  
 <223> n equals a,t,g, or c  
 <220>  
 <221> misc feature  
 <222> (23)  
 <223> n equals a,t,g, or c  
 <220>  
 <221> misc feature  
 <222> (24)  
 <223> n equals a,t,g, or c  
 <220>  
 <221> misc feature  
 <222> (25)  
 <223> n equals a,t,g, or c  
 <220>  
 <221> misc feature  
 <222> (26)  
 <223> n equals a,t,g, or c  
 <220>  
 <221> misc feature  
 <222> (27)  
 <223> n equals a,t,g, or c  
 <220>  
 <221> misc feature  
 <222> (28)  
 <223> n equals a,t,g, or c  
 <220>  
 <221> misc feature  
 <222> (29)  
 <223> n equals a,t,g, or c  
 <220>  
 <221> misc feature  
 <222> (30)  
 <223> n equals a,t,g, or c  
 <220>  
 <221> misc feature  
 <222> (31)  
 <223> n equals a,t,g, or c  
 <220>  
 <221> misc feature

MAILING ADDRESS OF SENDER

Finnegan, Henderson, Farabow,  
 Garrett & Dunner, L.L.P.  
 901 New York Avenue, N.W.  
 Washington, D.C. 20001-4413

U.S. Patent No. 6,926,898

JAN 04 2006

<222> (32)  
 <223> n equals a,t,g, or c  
 <220>  
 <221> misc feature  
 <222> (33)  
 <223> n equals a,t,g, or c  
  
 <400> 27  
 aggagcgtcg acaaaagann nnnnnnnnnn nnn  
  
 <210> 28  
 <211> 52  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <221> primer\_bind  
 <223> reverse primer useful for generation of albumin fusion protein in which  
 the albumin moiety is c-terminal of the Therapeutic Protein  
 <220>  
 <221> misc feature  
 <222> (38)  
 <223> n equals a,t,g, or c  
 <220>  
 <221> misc feature  
 <222> (39)  
 <223> n equals a,t,g, or c  
 <220>  
 <221> misc feature  
 <222> (40)  
 <223> n equals a,t,g, or c  
 <220>  
 <221> misc feature  
 <222> (41)  
 <223> n equals a,t,g, or c  
 <220>  
 <221> misc feature  
 <222> (42)  
 <223> n equals a,t,g, or c  
 <220>  
 <221> misc feature  
 <222> (43)  
 <223> n equals a,t,g, or c  
 <220>  
 <221> misc feature  
 <222> (44)  
 <223> n equals a,t,g, or c  
 <220>  
 <221> misc feature  
 <222> (45)  
 <223> n equals a,t,g, or c  
 <220>  
 <221> misc feature

33

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,  
 Garrett & Dunner, L.L.P.  
 901 New York Avenue, N.W.  
 Washington, D.C. 20001-4413

JAN 04 2006

```

<222> (46)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (47)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (48)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (49)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (50)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (51)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (52)
<223> n equals a,t,g, or c

<400> 28
ctttaaatcg atgagcaacc tcactcttgt gtgcacnnn nnnnnnnnnn nn          52

<210> 29
<211> 24
<212> PRT
<213> Artificial Sequence
<220>
<221> signal
<223> signal peptide of natural human serum albumin protein

<400> 29
Met Lys Trp Val Ser Phe Ile Ser Leu Leu Phe Leu Phe Ser Ser Ala
  1               5               10               15

Tyr Ser Arg Ser Leu Asp Lys Arg
      20

<210> 30
<211> 114
<212> DNA
<213> Artificial Sequence
<220>
<221> primer_bind
<223> forward primer useful for generation of PC4:HSA albumin fusion VECTOR

```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,  
Garrett & Dunner, L.L.P.  
901 New York Avenue, N.W.  
Washington, D.C. 20001-4413

JAN 04 2006

```

<220>
<221> misc_feature
<222> (5)..(10)
<223> BamHI restriction site
<220>
<221> misc_feature
<222> (11)..(16)
<223> Hind III restriction site
<220>
<221> misc_feature
<222> (17)..(27)
<223> Kozak sequence
<220>
<221> misc_feature
<222> (25)..(97)
<223> cds natural signal sequence of human serum albumin
<220>
<221> misc_feature
<222> (75)..(81)
<223> XhoI restriction site
<220>
<221> misc_feature
<222> (98)..(114)
<223> cds first six amino acids of human serum albumin

<400> 30
tcagggatcc aagcttccgc caccatgaag tgggtaacct ttatttcctc tctttttctc 60

ttagctcgg cttactcgag ggggtgtgtt cgctcgagatg cacacaagag tgag      114

<210> 31
<211> 43
<212> DNA
<213> Artificial Sequence
<220>
<221> primer_bind
<223> reverse primer useful for generation of PC4:HSA albumin fusion VECTOR
<220>
<221> misc_feature
<222> (6)..(11)
<223> Asp718 restriction site
<220>
<221> misc_feature
<222> (12)..(17)
<223> EcoRI restriction site
<220>
<221> misc_feature
<222> (15)..(17)
<223> reverse complement of stop codon
<220>
<221> misc_feature
<222> (18)..(25)

```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,  
Garrett & Dunner, L.L.P.  
901 New York Avenue, N.W.  
Washington, D.C. 20001-4413

JAN 04 2006

```

<223> AscI restriction site
<220>
<221> misc_feature
<222> (18)..(43)
<223> reverse complement of DNA sequence encoding last 9 amino acids

<400> 31
gcagcgggtac cgaattcggc ggcgccttata agcctaaggc agc
43

<210> 32
<211> 46
<212> DNA
<213> Artificial Sequence
<220>
<221> primer_bind
<223> forward primer useful for inserting Therapeutic protein into pC4:HSA
vector
<220>
<221> misc feature
<222> (29)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (30)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (31)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (32)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (33)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (34)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (35)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (36)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (37)

```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,  
Garrett & Dunner, L.L.P.  
901 New York Avenue, N.W.  
Washington, D.C. 20001-4413

JAN 04 2006

<223> n equals a,t,g, or c  
 <220>  
 <221> misc feature  
 <222> (38)  
 <223> n equals a,t,g, or c  
 <220>  
 <221> misc feature  
 <222> (39)  
 <223> n equals a,t,g, or c  
 <220>  
 <221> misc feature  
 <222> (40)  
 <223> n equals a,t,g, or c  
 <220>  
 <221> misc feature  
 <222> (41)  
 <223> n equals a,t,g, or c  
 <220>  
 <221> misc feature  
 <222> (42)  
 <223> n equals a,t,g, or c  
 <220>  
 <221> misc feature  
 <222> (43)  
 <223> n equals a,t,g, or c  
 <220>  
 <221> misc feature  
 <222> (44)  
 <223> n equals a,t,g, or c  
 <220>  
 <221> misc feature  
 <222> (45)  
 <223> n equals a,t,g, or c  
 <220>  
 <221> misc feature  
 <222> (46)  
 <223> n equals a,t,g, or c

<400> 32  
 ccgccgctcg aggggtgtgt ttcgtcgann nnnnnnnnnn nnnnnn

46

<210> 33  
 <211> 55  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <221> primer\_bind  
 <223> reverse primer useful for inserting Therapeutic protein into pC4:HSA  
 vector  
 <220>  
 <221> misc feature  
 <222> (38)

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,  
 Garrett & Dunner, L.L.P.  
 901 New York Avenue, N.W.  
 Washington, D.C. 20001-4413

JAN 04 2006

<223> n equals a,t,g, or c  
<220>  
<221> misc feature  
<222> (39)  
<223> n equals a,t,g, or c  
<220>  
<221> misc feature  
<222> (40)  
<223> n equals a,t,g, or c  
<220>  
<221> misc feature  
<222> (41)  
<223> n equals a,t,g, or c  
<220>  
<221> misc feature  
<222> (42)  
<223> n equals a,t,g, or c  
<220>  
<221> misc feature  
<222> (43)  
<223> n equals a,t,g, or c  
<220>  
<221> misc feature  
<222> (44)  
<223> n equals a,t,g, or c  
<220>  
<221> misc feature  
<222> (45)  
<223> n equals a,t,g, or c  
<220>  
<221> misc feature  
<222> (46)  
<223> n equals a,t,g, or c  
<220>  
<221> misc feature  
<222> (47)  
<223> n equals a,t,g, or c  
<220>  
<221> misc feature  
<222> (48)  
<223> n equals a,t,g, or c  
<220>  
<221> misc feature  
<222> (49)  
<223> n equals a,t,g, or c  
<220>  
<221> misc feature  
<222> (50)  
<223> n equals a,t,g, or c  
<220>  
<221> misc feature  
<222> (51)

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,  
Garrett & Dunner, L.L.P.  
901 New York Avenue, N.W.  
Washington, D.C. 20001-4413

JAN 04 2006

```

<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (52)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (53)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (54)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (55)
<223> n equals a,t,g, or c

<400> 33
agtcccatcg atgagcaacc tcactcttgt gtgcacnncnn nnnnnnnnnnn nnnnn      55

<210> 34
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<221> signal
<223> Stanniocalcin signal peptide

<400> 34
Met Leu Gln Asn Ser Ala Val Leu Leu Leu Leu Val Ile Ser Ala Ser Ala
  1              5              10              15

<210> 35
<211> 22
<212> PRT
<213> Artificial Sequence
<220>
<221> signal
<223> Synthetic signal peptide

<400> 35
Met Pro Thr Trp Ala Trp Trp Leu Phe Leu Val Leu Leu Leu Ala Leu
  1              5              10              15

Trp Ala Pro Ala Arg Gly
      20

<210> 36
<211> 23
<212> DNA
<213> Artificial Sequence
<220>

```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,  
Garrett & Dunner, L.L.P.  
901 New York Avenue, N.W.  
Washington, D.C. 20001-4413

JAN 04 2006

```

<221>primer_bind
<223>Degenerate VH forward primer useful for amplifying human VH domains

<400> 36
caggtgcagc tggcgcagtc tgg                                23

<210> 37
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate VH forward primer useful for amplifying human VH domains

<400> 37
caggtcaact taagggagtc tgg                                23

<210> 38
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate VH forward primer useful for amplifying human VH domains

<400> 38
gaggtgcagc tggcggagtc tgg                                23

<210> 39
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate VH forward primer useful for amplifying human VH domains

<400> 39
caggtgcagc tgcaggagtc ggg                                23

<210> 40
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate VH forward primer useful for amplifying human VH domains

<400> 40
gaggtgcagc tgttcagtc tgc                                23

<210> 41
<211> 23

```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,  
Garrett & Dunner, L.L.P.  
901 New York Avenue, N.W.  
Washington, D.C. 20001-4413

JAN 04 2006

<212> DNA  
 <213> Artificial Sequence  
 <220>  
 <221>primer\_bind  
 <223>Degenerate VH forward primer useful for amplifying human VH domains  
  
 <400> 41  
 caggtacagc tgcagcagtc agg 23  
  
 <210> 42  
 <211> 24  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <221>primer\_bind  
 <223>Degenerate JH reverse primer useful for amplifying human VH domains  
  
 <400> 42  
 tgaggagacg gtgaccaggg tgcc 24  
  
 <210> 43  
 <211> 24  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <221>primer\_bind  
 <223>Degenerate JH reverse primer useful for amplifying human VH domains  
  
 <400> 43  
 tgaagagacg gtgaccattg tccc 24  
  
 <210> 44  
 <211> 24  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <221>primer\_bind  
 <223>Degenerate JH reverse primer useful for amplifying human VH domains  
  
 <400> 44  
 tgaggagacg gtgaccaggg ttcc 24  
  
 <210> 45  
 <211> 24  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <221>primer\_bind  
 <223>Degenerate JH reverse primer useful for amplifying human VH domains  
  
 <400> 45  
 tgaggagacg gtgaccgtgg tccc 24

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,  
 Garrett & Dunner, L.L.P.  
 901 New York Avenue, N.W.  
 Washington, D.C. 20001-4413

JAN 04 2006

```

<210> 46
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate Vkappa forward primer useful for amplifying human VL domains

<400> 46
gacatccaga tgacccagtc tcc                                23

<210> 47
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate Vkappa forward primer useful for amplifying human VL domains

<400> 47
gatgttgtga tgactcagtc tcc                                23

<210> 48
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate Vkappa forward primer useful for amplifying human VL domains

<400> 48
gatattgtga tgactcagtc tcc                                23

<210> 49
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate Vkappa forward primer useful for amplifying human VL domains

<400> 49
gaaattgtgt tgacgcagtc tcc                                23

<210> 50
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate Vkappa forward primer useful for amplifying human VL domains

```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,  
Garrett & Dunner, L.L.P.  
901 New York Avenue, N.W.  
Washington, D.C. 20001-4413

JAN 04 2006

```

<400> 50
gacatcgtga tgacccagtc tcc                                23

<210> 51
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate Vkappa forward primer useful for amplifying human VL domains

<400> 51
gaaacgacac tcacgcagtc tcc                                23

<210> 52
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate Vkappa forward primer useful for amplifying human VL domains

<400> 52
gaaattgtgc tgactcagtc tcc                                23

<210> 53
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate Vlambda forward primer useful for amplifying human VL domains

<400> 53
cagtctgtgt tgacgcagcc gcc                                23

<210> 54
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate Vlambda forward primer useful for amplifying human VL domains

<400> 54
cagtctgccc tgactcagcc tgc                                23

<210> 55
<211> 23
<212> DNA
<213> Artificial Sequence
<220>

```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,  
Garrett & Dunner, L.L.P.  
901 New York Avenue, N.W.  
Washington, D.C. 20001-4413

JAN 04 2006

```

<221>primer_bind
<223>Degenerate Vlambda forward primer useful for amplifying human VL domains

<400> 55
tcctatgtgc tgactcagcc acc                                23

<210> 56
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221>primer_bind
<223>Degenerate Vlambda forward primer useful for amplifying human VL domains

<400> 56
tcttctgagc tgactcagga ccc                                23

<210> 57
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate Vlambda forward primer useful for amplifying human VL domains

<400> 57
cacgttatac tgactcaacc gcc                                23

<210> 58
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate Vlambda forward primer useful for amplifying human VL domains

<400> 58
caggctgtgc tcactcagcc gtc                                23

<210> 59
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate Vlambda forward primer useful for amplifying human VL domains

<400> 59
aattttatgc tgactcagcc cca                                23

```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,  
Garrett & Dunner, L.L.P.  
901 New York Avenue, N.W.  
Washington, D.C. 20001-4413

JAN 04 2006

```

<210> 60
<211> 24
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate Jkappa reverse primer useful for amplifying human VL domains

<400> 60
acgtttgatt tccaccttgg tccc                24

<210> 61
<211> 24
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate Jkappa reverse primer useful for amplifying human VL domains

<400> 61
acgtttgatc tccagcttgg tccc                24

<210> 62
<211> 24
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate Jkappa reverse primer useful for amplifying human VL domains

<400> 62
acgtttgata tccactttgg tccc                24

<210> 63
<211> 24
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate Jkappa reverse primer useful for amplifying human VL domains

<400> 63
acgtttgatc tccaccttgg tccc                24

<210> 64
<211> 24
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate Jkappa reverse primer useful for amplifying human VL domains

```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,  
Garrett & Dunner, L.L.P.  
901 New York Avenue, N.W.  
Washington, D.C. 20001-4413

JAN 04 2006

<400> 64  
 acgtttaatc tccagtcgtg tccc 24  
  
 <210> 65  
 <211> 23  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <221>primer\_bind  
 <223>Degenerate Jlambda reverse primer useful for amplifying human VL domains  
  
 <400> 65  
 cagtctgtgt tgacgcagcc gcc 23  
  
 <210> 66  
 <211> 23  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <221>primer\_bind  
 <223>Degenerate Jlambda reverse primer useful for amplifying human VL domains  
  
 <400> 66  
 cagtctgccc tgactcagcc tgc 23  
  
 <210> 67  
 <211> 23  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <221>primer\_bind  
 <223>Degenerate Jlambda reverse primer useful for amplifying human VL domains  
  
 <400> 67  
 tcctatgtgc tgactcagcc acc 23  
  
 <210> 68  
 <211> 23  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <221>primer\_bind  
 <223>Degenerate Jlambda reverse primer useful for amplifying human VL domains  
  
 <400> 68  
 tcttctgagc tgactcagga ccc 23  
  
 <210> 69  
 <211> 23  
 <212> DNA  
 <213> Artificial Sequence  
 <220>

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,  
 Garrett & Dunner, L.L.P.  
 901 New York Avenue, N.W.  
 Washington, D.C. 20001-4413

JAN 04 2006

```

<221>primer_bind
<223>Degenerate Jlambda reverse primer useful for amplifying human VL domains

<400> 69
cacgttatac tgactcaacc gcc                                23

<210> 70
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate Jlambda reverse primer useful for amplifying human VL domains

<400> 70
caggctgtgc tcaactcagcc gtc                                23

<210> 71
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate Jlambda reverse primer useful for amplifying human VL domains

<400> 71
aattttatgc tgactcagcc cca                                23

<210> 72
<211> 15
<212> PRT
<213> Artificial Sequence
<220>
<221>turn
<223>Linker peptide that may be used to join VH and VL domains in an scFv.

<400> 72
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
  1             5             10             15

<210> 73
<211> 733
<212> DNA
<213> Homo sapiens

<400> 73
gggatccgga gcccaaattct tctgacaaaa ctcacacatg cccaccgtgc ccagcacctg      60
aattcgaggg tgcaccgtca gtcttcctct tccccccaaa acccaaggac accctcatga      120
tctcccggaac tcttgaggtc acatgcgtgg tgggtggacgt aagccacgaa gaccctgagg      180

```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,  
Garrett & Dunner, L.L.P.  
901 New York Avenue, N.W.  
Washington, D.C. 20001-4413

JAN 04 2006

tcaagttcaa ctggtacgtg gacggcgtgg aggtgcataa tgccaagaca aagccgcggg	240
aggagcagta caacagcacg taccgtgtgg tcagcgtcct caccgtcctg caccaggact	300
ggctgaatgg caaggagtac aagtgcaagg tctccaacaa agccctccca acccccatcg	360
agaaaaccat ctccaaagcc aaagggcagc cccgagaacc acaggtgtac accctgcccc	420
catcccggga tgagctgacc aagaaccagg tcagcctgac ctgcctggtc aaaggcttct	480
atccaagcga catcgccgtg gagtgggaga gcaatgggca gccggagaac aactacaaga	540
ccacgcctcc cgtgctggac tccgacggct ctttcttctt ctacagcaag ctcaccgtgg	600
acaagagcag gtggcagcag gggaaacgtct tctcatgctc cgtgatgcat gaggctctgc	660
acaaccacta cagcagaag agcctctccc tgtctccggg taaatgagtg cgacggccgc	720
gactctagag gat	733

<210> 74  
 <211> 5  
 <212> PRT  
 <213> Artificial sequence  
 <220>  
 <221> misc\_structure  
 <223> membrane proximal motif of class 1 cytokine receptors  
 <220>  
 <221> misc\_feature  
 <222> (3)  
 <223> Xaa equals any

<400> 74  
 Trp Ser Xaa Trp Ser  
 1 5

<210> 75  
 <211> 86  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <221> primer\_bind  
 <223> forward primer useful for generation of a synthetic gamma activation site (GAS) containing promoter element

<400> 75	
gcgctcgag atttccccga aatctagatt tccccgaaat gatttccccg aaatgatttc	60
cccgaaatat ctgccatctc aattag	86

<210> 76  
 <211> 27

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,  
 Garrett & Dunner, L.L.P.  
 901 New York Avenue, N.W.  
 Washington, D.C. 20001-4413

JAN 04 2006

<212> DNA  
 <213> Artificial Sequence  
 <220>  
 <221> primer\_bind  
 <223> reverse primer useful for generation of a synthetic gamma activation site (GAS) containing promoter element

<400> 76  
 gcggcaagct ttttgcaaag cctaggc 27

<210> 77  
 <211> 271  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <221> misc\_feature  
 <223> Synthetic GAS-SV40 promoter sequence

<400> 77  
 ctcgagattt ccccgaaatc tagatttccc cgaaatgatt tccccgaaat gatttccccg 60  
 aaatatctgc catctcaatt agtcagcaac catagtcccg cccctaactc cgcccatccc 120  
 gccctaact ccgcccagtt ccgcccattc tccgcccatt ggctgactaa ttttttttat 180  
 ttatgcagag gccgaggccg cctcggcctc tgagctattc cagaagtagt gaggaggctt 240  
 ttttgagggc ctaggctttt gcaaaaagct t 271

<210> 78  
 <211> 32  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <221> primer\_bind  
 <223> primer useful for generation of a EGR/SEAP reporter construct

<400> 78  
 gcgctcgagg gatgacagcg atagaacccc gg 32

<210> 79  
 <211> 31  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <221> primer\_bind  
 <223> primer useful for generation of a EGR/SEAP reporter construct

<400> 79  
 gcgaagcttc gcgactcccc ggatccgctt c 31

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,  
 Garrett & Dunner, L.L.P.  
 901 New York Avenue, N.W.  
 Washington, D.C. 20001-4413

JAN 04 2006

<210> 80  
 <211> 12  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <221> misc\_binding  
 <223> NF-KB binding site

<400> 80  
 ggggactttc cc 12

<210> 81  
 <211> 73  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <221> primer\_bind  
 <223> forward primer useful for generation of a vector containing the NF-KB promoter element

<400> 81  
 gcggcctcga ggggactttc ccggggactt tccggggact ttccgggact ttccatcctg 60  
 ccattctcaat tag 73

<210> 82  
 <211> 256  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <221> misc\_feature  
 <223> Synthetic NF-KB/SV40 promoter

<400> 82  
 ctcgagggga ctttcccgga gactttccgg ggactttccg ggactttcca tctgccatct 60  
 caattagtca gcaaccatag tcccgccctt aactccgccc atcccgcccc taactccgcc 120  
 cagttccgcc cattctccgc cccatggctg actaattttt tttatttatg cagaggccga 180  
 ggccgcctcg gcctctgagc tattccagaa gtagtgagga ggcttttttg gaggcctagg 240  
 cttttgcaaa aagctt 256

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,  
 Garrett & Dunner, L.L.P.  
 901 New York Avenue, N.W.  
 Washington, D.C. 20001-4413

JAN 04 2006

**UNITED STATES PATENT AND TRADEMARK OFFICE**  
**CERTIFICATE OF CORRECTION**

PATENT NO. 6,926,898

Page 1 of 35

APPLICATION NO.: 09/832,929

ISSUE DATE: August 9, 2005

INVENTOR(S): Craig A. Rosen and William A. Haseltine

It is hereby certified that an error or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Under item (60) (Related U.S. Application Data) of the title page, delete the text beginning with "Provisional application No. 60/256,931" to and ending "provisional application No. 60/229,358, filed on Apr. 12, 2000."

Under item (56) (References Cited) of the title page and under U.S. PATENT DOCUMENTS beginning on page 1, insert:

--	2003-0022308 A1	1/2003	Fleer et al.
	2003-0036170 A1	2/2003	Fleer et al.
	2003-0036171 A1	2/2003	Fleer et al.
	2003-0036172 A1	2/2003	Fleer et al.
	2003-0054554 A1	3/2003	Becquart et al.
	2003-0082747 A1	5/2003	Fleer et al.
	2003-0104578 A1	10/2001	Ballance
	2004-0010134 A1	4/2001	Rosen et al.
	09/832,501	4/2001	Ballance et al.
	09/833,041	4/2001	Rosen et al.
	09/833,111	4/2001	Rosen et al.
	09/833,117	4/2001	Rosen et al.
	09/833,118	4/2001	Rosen et al.
	10/702,536	11/2003	Fleer et al.
	10/702,636	11/2003	Fleer et al. --

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,  
Garrett & Dunner, L.L.P.  
901 New York Avenue, N.W.  
Washington, D.C. 20001-4413

JAN 04 2006

Under item (56) (References Cited) of the title page and under OTHER PUBLICATIONS beginning on page 1, insert:

- Larsson, M., et al., "Role of Annexins in Endocytosis of Antigens in Immature Human Dendritic Cells," *Immunology* 92:501-511 (1997).
- Latta, M. et al., "Synthesis and Purification of Mature Human Serum Albumin From *E. Coli*," *Bio/Technology* 5:1309-1314 (1987).
- Latta, M., et al., "Tryptophan Promoter Derivatives on Multicopy Plasmids: A Comparative Analysis of Expression Potentials in *Escherichia coli*," *DNA and Cell Biology* 9:129-137 (1990).
- Lawn, R.M., et al., "The Sequence of Human Serum Albumin cDNA and its Expression in *E. coli*," *Nucleic Acids Research* 9:6103-6113 (1981).
- Le Bras, M., et al., "Epidemiologie et Clinique des Maladies Tropicales D'importation," *La Revue de Medicine Interne* 13:205-210 (1992), with English translation.
- Leblois, H., et al., "Stable Transduction of Actively Dividing Cells via a Novel Adenoviral/Episomal Vector," *Molecular Therapy* 1:314-322 (2000).
- Lee, C-H., et al., "Sodium Pertechnetate Tc99m Antral Scan in the Diagnosis of Retained Gastric Antrum," *Arch. Surg.* 119: 309-311 (1984).
- Lee, C-L., et al., "Preparation and Characterization of Polyethylene-Glycol-Modified Salmon Calcitonins," *Pharmaceutical Development and Technology*, 4(2): 269-275 (1999).
- Lee, W-C., et al., "Identification and Characterization of a Nuclear Localization Sequence-Binding Protein in Yeast," *Proc. Natl. Acad. Sci. USA* 86:8808-8812 (1989).
- Lee, Y-H., et al., "Comparison of Effective Renal Plasma Flow (ERPF) and Endogenous Creatinine Clearance (Ccr) in Evaluation of the Differential Kidney Function: An in Vivo Study," *Chin. Med. J. (Taipei)* 49:147-152 (1992).
- Lei, H-Y., et al., "An Antigen-specific Hypersensitivity Which Does Not Fit Into Traditional Classification of Hypersensitivity," *The Journal of Immunology* 143:432-438 (1989).
- Levitt, D., et al., "Toxicity of Perfluorinated Fatty-Acids for Human and Murine B Cell Lines," *Toxicology and Applied Pharmacology* 86:1-11 (1986).

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,  
Garrett & Dunner, L.L.P.  
901 New York Avenue, N.W.  
Washington, D.C. 20001-4413

JAN 04 2006

Lew D.B., et al., "Mitogenic Effect of Lysosomal Hydrolases on Bovine Tracheal Myocytes in Culture," *The Journal of Clinical Investigation* 88:1969-1975 (1991).

Lewis, C., et al., "Is Sexual Dysfunctoin in Hypertensive Women Uncommon or Understudied?" *American Jour of Hypertension*," 11:733-735 (1998). --

Under item (57) (ABSTRACT) of the title page, "disordrs" should read --disorders--.

In the Specification

Col. 143, line 26, delete "As exhibited in Table 2, most", and insert --Most--.

Col. 143, line 31, delete "Table 2".

In the Claims

Col. 340, line 40, delete "an".

Col. 340, line 47, delete "an".

In the Sequence Listing

Delete the Sequence Listing beginning in Col. 299, beginning with the text "<160> NUMBER OF SEQ ID NOS: 72" to and ending "<400> SEQUENCE: 72

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser  
1 5 10 15"

in Col. 340 and insert the following Sequence Listing:

<160> NUMBER OF SEQ ID NOS: 82

<210> 1

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> primer\_bind

<223> primer useful to clone human growth hormone cDNA

<400> 1

cccaagaatt cccttatcca ggc

23

<210> 2

<211> 33

<212> DNA

<213> Artificial Sequence

<220>

<221> primer\_bind

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,  
Garrett & Dunner, L.L.P.  
901 New York Avenue, N.W.  
Washington, D.C. 20001-4413

JAN 04 2006

<223> primer useful to clone human growth hormone cDNA

<400> 2  
gggaagctta gaagccacag gatccctcca cag 33

<210> 3  
<211> 16  
<212> DNA  
<213> Artificial Sequence  
<220>  
<221> misc\_structure  
<223> synthetic oligonucleotide used to join DNA fragments with non-cohesive ends.

<400> 3  
gataaagatt cccaac 16

<210> 4  
<211> 17  
<212> DNA  
<213> Artificial Sequence  
<220>  
<221> misc\_structure  
<223> synthetic oligonucleotide used to join DNA fragments with non-cohesive ends.

<400> 4  
aattgttggg aatcttt 17

<210> 5  
<211> 17  
<212> DNA  
<213> Artificial Sequence  
<220>  
<221> misc\_structure  
<223> synthetic oligonucleotide used to join DNA fragments with non-cohesive ends.

<400> 5  
ttaggcttat tcccaac 17

<210> 6  
<211> 18  
<212> DNA  
<213> Artificial Sequence  
<220>  
<221> misc\_structure  
<223> synthetic oligonucleotide used to join DNA fragments with non-cohesive ends.

<400> 6  
aattgttggg aataagcc 18

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,  
Garrett & Dunner, L.L.P.  
901 New York Avenue, N.W.  
Washington, D.C. 20001-4413

JAN 04 2006

```

<210> 7
<211> 24
<212> PRT
<213> Artificial Sequence
<220>
<221> SITE
<222> 1)..(19)
<223> invertase leader sequence
<220>
<221> SITE
<222> 20)..(24)
<223> first 5 amino acids of mature human serum albumin

<400> 7
Met Leu Leu Gln Ala Phe Leu Phe Leu Leu Ala Gly Phe Ala Ala Lys
  1             5             10             15

Ile Ser Ala Asp Ala His Lys Ser
          20

<210> 8
<211> 21
<212> DNA
<213> Artificial Sequence
<220>
<221> misc_structure
<223> synthetic oligonucleotide used to join DNA fragments with non-cohesive
ends.

<400> 8
gagatgcaca cctgagtgag g
                                     21

<210> 9
<211> 27
<212> DNA
<213> Artificial Sequence
<220>
<221> misc_structure
<223> synthetic oligonucleotide used to join DNA fragments with non-cohesive
ends.

<400> 9
gatcctgtgg cttcgatgca cacaaga
                                     27

<210> 10
<211> 24
<212> DNA
<213> Artificial Sequence
<220>
<221> misc_structure
<223> synthetic oligonucleotide used to join DNA fragments with non-cohesive
ends.

```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,  
Garrett & Dunner, L.L.P.  
901 New York Avenue, N.W.  
Washington, D.C. 20001-4413

JAN 04 2006

<400> 10	24
ctcttgtgtg catcgaagcc acag	
<210> 11	
<211> 30	
<212> DNA	
<213> Artificial Sequence	
<220>	
<221> misc_structure	
<223> synthetic oligonucleotide used to join DNA fragments with non-cohesive ends.	
<400> 11	30
tgtggaagag cctcagaatt tattcccaac	
<210> 12	
<211> 31	
<212> DNA	
<213> Artificial Sequence	
<220>	
<221> misc_structure	
<223> synthetic oligonucleotide used to join DNA fragments with non-cohesive ends.	
<400> 12	31
aattgttggg aataaattct gaggtcttcc c	
<210> 13	
<211> 47	
<212> DNA	
<213> Artificial Sequence	
<220>	
<221> misc_structure	
<223> synthetic oligonucleotide used to join DNA fragments with non-cohesive ends.	
<400> 13	47
ttaggttag gtggcggtgg atccggcggt ggtggatctt tcccaac	
<210> 14	
<211> 48	
<212> DNA	
<213> Artificial Sequence	
<220>	
<221> misc_structure	
<223> synthetic oligonucleotide used to join DNA fragments with non-cohesive ends.	
<400> 14	48
aattgttggg aaagatccac caccgccgga tccaccgccca cctaagcc	

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,  
Garrett & Dunner, L.L.P.  
901 New York Avenue, N.W.  
Washington, D.C. 20001-4413

JAN 04 2006

<210> 15  
 <211> 62  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <221> misc\_structure  
 <223> synthetic oligonucleotide used to join DNA  
 fragments with non-cohesive ends.

<400> 15  
 ttaggcttag gcggtggtgg atctggtggc ggcggatctg gtggcgggtgg atccttccca 60  
 ac 62

<210> 16  
 <211> 63  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <221> misc\_structure  
 <223> synthetic oligonucleotide used to join DNA  
 fragments with non-cohesive ends.

<400> 16  
 aattgttggg aaggatccac cgccaccaga tccgccgccca ccagatccac caccgcctaa 60  
 gcc 63

<210> 17  
 <211> 1782  
 <212> DNA  
 <213> Homo sapiens  
 <220>  
 <221> CDS  
 <222> (1)..(1755)

<400> 17  
 gat gca cac aag agt gag gtt gct cat cgg ttt aaa gat ttg gga gaa 48  
 Asp Ala His Lys Ser Glu Val Ala His Arg Phe Lys Asp Leu Gly Glu  
 1 5 10 15

gaa aat ttc aaa gcc ttg gtg ttg att gcc ttt gct cag tat ctt cag 96  
 Glu Asn Phe Lys Ala Leu Val Leu Ile Ala Phe Ala Gln Tyr Leu Gln  
 20 25 30

cag tgt cca ttt gaa gat cat gta aaa tta gtg aat gaa gta act gaa 144  
 Gln Cys Pro Phe Glu Asp His Val Lys Leu Val Asn Glu Val Thr Glu  
 35 40 45

ttt gca aaa aca tgt gtt gct gat gag tca gct gaa aat tgt gac aaa 192  
 Phe Ala Lys Thr Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys  
 50 55 60

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,  
 Garrett & Dunner, L.L.P.  
 901 New York Avenue, N.W.  
 Washington, D.C. 20001-4413

JAN 04 2006

tca ctt cat acc ctt ttt gga gac aaa tta tgc aca gtt gca act ctt	240
Ser Leu His Thr Leu Phe Gly Asp Lys Leu Cys Thr Val Ala Thr Leu	
65 70 75 80	
cgt gaa acc tat ggt gaa atg gct gac tgc tgt gca aaa caa gaa cct	288
Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys Cys Ala Lys Gln Glu Pro	
85 90 95	
gag aga aat gaa tgc ttc ttg caa cac aaa gat gac aac cca aac ctc	336
Glu Arg Asn Glu Cys Phe Leu Gln His Lys Asp Asp Asn Pro Asn Leu	
100 105 110	
ccc cga ttg gtg aga cca gag gtt gat gtg atg tgc act gct ttt cat	384
Pro Arg Leu Val Arg Pro Glu Val Asp Val Met Cys Thr Ala Phe His	
115 120 125	
gac aat gaa gag aca ttt ttg aaa aaa tac tta tat gaa att gcc aga	432
Asp Asn Glu Glu Thr Phe Leu Lys Lys Tyr Leu Tyr Glu Ile Ala Arg	
130 135 140	
aga cat cct tac ttt tat gcc ccg gaa ctc ctt ttc ttt gct aaa agg	480
Arg His Pro Tyr Phe Tyr Ala Pro Glu Leu Leu Phe Phe Ala Lys Arg	
145 150 155 160	
tat aaa gct gct ttt aca gaa tgt tgc caa gct gct gat aaa gct gcc	528
Tyr Lys Ala Ala Phe Thr Glu Cys Cys Gln Ala Ala Asp Lys Ala Ala	
165 170 175	
tgc ctg ttg cca aag ctc gat gaa ctt cgg gat gaa ggg aag gct tcg	576
Cys Leu Leu Pro Lys Leu Asp Glu Leu Arg Asp Glu Gly Lys Ala Ser	
180 185 190	
tct gcc aaa cag aga ctc aaa tgt gcc agt ctc caa aaa ttt gga gaa	624
Ser Ala Lys Gln Arg Leu Lys Cys Ala Ser Leu Gln Lys Phe Gly Glu	
195 200 205	
aga gct ttc aaa gca tgg gca gtg gct cgc ctg agc cag aga ttt ccc	672
Arg Ala Phe Lys Ala Trp Ala Val Ala Arg Leu Ser Gln Arg Phe Pro	
210 215 220	
aaa gct gag ttt gca gaa gtt tcc aag tta gtg aca gat ctt acc aaa	720
Lys Ala Glu Phe Ala Glu Val Ser Lys Leu Val Thr Asp Leu Thr Lys	
225 230 235 240	
gtc cac acg gaa tgc tgc cat gga gat ctg ctt gaa tgt gct gat gac	768
Val His Thr Glu Cys Cys His Gly Asp Leu Leu Glu Cys Ala Asp Asp	
245 250 255	
agg gcg gac ctt gcc aag tat atc tgt gaa aat cag gat tcg atc tcc	816
Arg Ala Asp Leu Ala Lys Tyr Ile Cys Glu Asn Gln Asp Ser Ile Ser	
260 265 270	

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,  
Garrett & Dunner, L.L.P.  
901 New York Avenue, N.W.  
Washington, D.C. 20001-4413

JAN 04 2006

agt aaa ctg aag gaa tgc tgt gaa aaa cct ctg ttg gaa aaa tcc cac	864
Ser Lys Leu Lys Glu Cys Cys Glu Lys Pro Leu Leu Glu Lys Ser His	
275 280 285	
tgc att gcc gaa gtg gaa aat gat gag atg cct gct gac ttg cct tca	912
Cys Ile Ala Glu Val Glu Asn Asp Glu Met Pro Ala Asp Leu Pro Ser	
290 295 300	
tta gct gct gat ttt gtt gaa agt aag gat gtt tgc aaa aac tat gct	960
Leu Ala Ala Asp Phe Val Glu Ser Lys Asp Val Cys Lys Asn Tyr Ala	
305 310 315 320	
gag gca aag gat gtc ttc ctg ggc atg ttt ttg tat gaa tat gca aga	1008
Glu Ala Lys Asp Val Phe Leu Gly Met Phe Leu Tyr Glu Tyr Ala Arg	
325 330 335	
agg cat cct gat tac tct gtc gtg ctg ctg ctg aga ctt gcc aag aca	1056
Arg His Pro Asp Tyr Ser Val Val Leu Leu Leu Arg Leu Ala Lys Thr	
340 345 350	
tat gaa acc act cta gag aag tgc tgt gcc gct gca gat cct cat gaa	1104
Tyr Glu Thr Thr Leu Glu Lys Cys Cys Ala Ala Ala Asp Pro His Glu	
355 360 365	
tgc tat gcc aaa gtg ttc gat gaa ttt aaa cct ctt gtg gaa gag cct	1152
Cys Tyr Ala Lys Val Phe Asp Glu Phe Lys Pro Leu Val Glu Glu Pro	
370 375 380	
cag aat tta atc aaa caa aac tgt gag ctt ttt gag cag ctt gga gag	1200
Gln Asn Leu Ile Lys Gln Asn Cys Glu Leu Phe Glu Gln Leu Gly Glu	
385 390 395 400	
tac aaa ttc cag aat gcg cta tta gtt cgt tac acc aag aaa gta ccc	1248
Tyr Lys Phe Gln Asn Ala Leu Leu Val Arg Tyr Thr Lys Lys Val Pro	
405 410 415	
caa gtg tca act cca act ctt gta gag gtc tca aga aac cta gga aaa	1296
Gln Val Ser Thr Pro Thr Leu Val Glu Val Ser Arg Asn Leu Gly Lys	
420 425 430	
gtg ggc agc aaa tgt tgt aaa cat cct gaa gca aaa aga atg ccc tgt	1344
Val Gly Ser Lys Cys Cys Lys His Pro Glu Ala Lys Arg Met Pro Cys	
435 440 445	
gca gaa gac tat cta tcc gtg gtc ctg aac cag tta tgt gtg ttg cat	1392
Ala Glu Asp Tyr Leu Ser Val Val Leu Asn Gln Leu Cys Val Leu His	
450 455 460	
gag aaa acg cca gta agt gac aga gtc aca aaa tgc tgc aca gag tcc	1440
Glu Lys Thr Pro Val Ser Asp Arg Val Thr Lys Cys Cys Thr Glu Ser	
465 470 475 480	

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,  
Garrett & Dunner, L.L.P.  
901 New York Avenue, N.W.  
Washington, D.C. 20001-4413

JAN 04 2006

```

ttg gtg aac agg cga cca tgc ttt tca gct ctg gaa gtc gat gaa aca 1488
Leu Val Asn Arg Arg Pro Cys Phe Ser Ala Leu Glu Val Asp Glu Thr
485 490 495

tac gtt ccc aaa gag ttt aat gct gaa aca ttc acc ttc cat gca gat 1536
Tyr Val Pro Lys Glu Phe Asn Ala Glu Thr Phe Thr Phe His Ala Asp
500 505 510

ata tgc aca ctt tct gag aag gag aga caa atc aag aaa caa act gca 1584
Ile Cys Thr Leu Ser Glu Lys Glu Arg Gln Ile Lys Lys Gln Thr Ala
515 520 525

ctt gtt gag ctt gtg aaa cac aag ccc aag gca aca aaa gag caa ctg 1632
Leu Val Glu Leu Val Lys His Lys Pro Lys Ala Thr Lys Glu Gln Leu
530 535 540

aaa gct gtt atg gat gat ttc gca gct ttt gta gag aag tgc tgc aag 1680
Lys Ala Val Met Asp Asp Phe Ala Ala Phe Val Glu Lys Cys Cys Lys
545 550 555 560

gct gac gat aag gag acc tgc ttt gcc gag gag ggt aaa aaa ctt gtt 1728
Ala Asp Asp Lys Glu Thr Cys Phe Ala Glu Glu Gly Lys Lys Leu Val
565 570 575

gct gca agt caa gct gcc tta ggc tta taacatctac atttaaaagc atctcag 1782
Ala Ala Ser Gln Ala Ala Leu Gly Leu
580 585

<210> 18
<211> 585
<212> PRT
<213> Homo Sapiens

<400> 18
Asp Ala His Lys Ser Glu Val Ala His Arg Phe Lys Asp Leu Gly Glu
1 5 10 15

Glu Asn Phe Lys Ala Leu Val Leu Ile Ala Phe Ala Gln Tyr Leu Gln
20 25 30

Gln Cys Pro Phe Glu Asp His Val Lys Leu Val Asn Glu Val Thr Glu
35 40 45

Phe Ala Lys Thr Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys
50 55 60

Ser Leu His Thr Leu Phe Gly Asp Lys Leu Cys Thr Val Ala Thr Leu
65 70 75 80

Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys Cys Ala Lys Gln Glu Pro
85 90 95

```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,  
Garrett & Dunner, L.L.P.  
901 New York Avenue, N.W.  
Washington, D.C. 20001-4413

JAN 04 2005

Glu	Arg	Asn	Glu	Cys	Phe	Leu	Gln	His	Lys	Asp	Asp	Asn	Pro	Asn	Leu	100	105	110
Pro	Arg	Leu	Val	Arg	Pro	Glu	Val	Asp	Val	Met	Cys	Thr	Ala	Phe	His	115	120	125
Asp	Asn	Glu	Glu	Thr	Phe	Leu	Lys	Lys	Tyr	Leu	Tyr	Glu	Ile	Ala	Arg	130	135	140
Arg	His	Pro	Tyr	Phe	Tyr	Ala	Pro	Glu	Leu	Leu	Phe	Phe	Ala	Lys	Arg	145	150	155
Tyr	Lys	Ala	Ala	Phe	Thr	Glu	Cys	Cys	Gln	Ala	Ala	Asp	Lys	Ala	Ala	165	170	175
Cys	Leu	Leu	Pro	Lys	Leu	Asp	Glu	Leu	Arg	Asp	Glu	Gly	Lys	Ala	Ser	180	185	190
Ser	Ala	Lys	Gln	Arg	Leu	Lys	Cys	Ala	Ser	Leu	Gln	Lys	Phe	Gly	Glu	195	200	205
Arg	Ala	Phe	Lys	Ala	Trp	Ala	Val	Ala	Arg	Leu	Ser	Gln	Arg	Phe	Pro	210	215	220
Lys	Ala	Glu	Phe	Ala	Glu	Val	Ser	Lys	Leu	Val	Thr	Asp	Leu	Thr	Lys	225	230	235
Val	His	Thr	Glu	Cys	Cys	His	Gly	Asp	Leu	Leu	Glu	Cys	Ala	Asp	Asp	245	250	255
Arg	Ala	Asp	Leu	Ala	Lys	Tyr	Ile	Cys	Glu	Asn	Gln	Asp	Ser	Ile	Ser	260	265	270
Ser	Lys	Leu	Lys	Glu	Cys	Cys	Glu	Lys	Pro	Leu	Leu	Glu	Lys	Ser	His	275	280	285
Cys	Ile	Ala	Glu	Val	Glu	Asn	Asp	Glu	Met	Pro	Ala	Asp	Leu	Pro	Ser	290	295	300
Leu	Ala	Ala	Asp	Phe	Val	Glu	Ser	Lys	Asp	Val	Cys	Lys	Asn	Tyr	Ala	305	310	315
Glu	Ala	Lys	Asp	Val	Phe	Leu	Gly	Met	Phe	Leu	Tyr	Glu	Tyr	Ala	Arg	325	330	335
Arg	His	Pro	Asp	Tyr	Ser	Val	Val	Leu	Leu	Leu	Arg	Leu	Ala	Lys	Thr	340	345	350
Tyr	Glu	Thr	Thr	Leu	Glu	Lys	Cys	Cys	Ala	Ala	Ala	Asp	Pro	His	Glu	355	360	365

MAILING ADDRESS OF SENDER

Finnegan, Henderson, Farabow,  
Garrett & Dunner, L.L.P.  
901 New York Avenue, N.W.  
Washington, D.C. 20001-4413

U.S. Patent No. 6,926,898

JAN 04 2006

Cys Tyr Ala Lys Val Phe Asp Glu Phe Lys Pro Leu Val Glu Glu Pro  
 370 375 380  
 Gln Asn Leu Ile Lys Gln Asn Cys Glu Leu Phe Glu Gln Leu Gly Glu  
 385 390 395 400  
 Tyr Lys Phe Gln Asn Ala Leu Leu Val Arg Tyr Thr Lys Lys Val Pro  
 405 410 415  
 Gln Val Ser Thr Pro Thr Leu Val Glu Val Ser Arg Asn Leu Gly Lys  
 420 425 430  
 Val Gly Ser Lys Cys Cys Lys His Pro Glu Ala Lys Arg Met Pro Cys  
 435 440 445  
 Ala Glu Asp Tyr Leu Ser Val Val Leu Asn Gln Leu Cys Val Leu His  
 450 455 460  
 Glu Lys Thr Pro Val Ser Asp Arg Val Thr Lys Cys Cys Thr Glu Ser  
 465 470 475 480  
 Leu Val Asn Arg Arg Pro Cys Phe Ser Ala Leu Glu Val Asp Glu Thr  
 485 490 495  
 Tyr Val Pro Lys Glu Phe Asn Ala Glu Thr Phe Thr Phe His Ala Asp  
 500 505 510  
 Ile Cys Thr Leu Ser Glu Lys Glu Arg Gln Ile Lys Lys Gln Thr Ala  
 515 520 525  
 Leu Val Glu Leu Val Lys His Lys Pro Lys Ala Thr Lys Glu Gln Leu  
 530 535 540  
 Lys Ala Val Met Asp Asp Phe Ala Ala Phe Val Glu Lys Cys Cys Lys  
 545 550 555 560  
 Ala Asp Asp Lys Glu Thr Cys Phe Ala Glu Glu Gly Lys Lys Leu Val  
 565 570 575  
 Ala Ala Ser Gln Ala Ala Leu Gly Leu  
 580 585

<210> 19

<211> 58

<212> DNA

<213> Artificial Sequence

<220>

<221> primer\_bind

<223> primer used to generate XhoI and ClaI site in pPPC0006

<400> 19

gcctcgagaa aagagatgca cacaagagtg aggttgctca tcgatttaaa gatttggg 58

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,  
 Garrett & Dunner, L.L.P.  
 901 New York Avenue, N.W.  
 Washington, D.C. 20001-4413

JAN 04 2006

<210> 20  
 <211> 59  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <221> primer\_bind  
 <223> primer used in generation XhoI and ClaI site in pPPC0006  
  
 <400> 20  
 aatcgatgag caacctcact cttgtgtgca tctcttttct cgaggctcct ggaataagc 59  
  
 <210> 21  
 <211> 24  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <221> primer\_bind  
 <223> primer used in generation XhoI and ClaI site in pPPC0006  
  
 <400> 21  
 tacaaactta agagtccaat tagc 24  
  
 <210> 22  
 <211> 29  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <221> primer\_bind  
 <223> primer used in generation XhoI and ClaI site in pPPC0006  
  
 <400> 22  
 cacttctcta gagggtttc atatgtctt 29  
  
 <210> 23  
 <211> 60  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <221> Misc\_Structure  
 <223> Synthetic oligonucleotide used to alter restriction sites in pPPC0007  
  
 <400> 23  
 aagctgcctt aggcttataa taaggcgcgc cggccggccg tttaaactaa gcttaattct 60  
  
 <210> 24  
 <211> 60  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <221> Misc\_Structure  
 <223> Synthetic oligonucleotide used to alter restriction sites in pPPC0007

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,  
 Garrett & Dunner, L.L.P.  
 901 New York Avenue, N.W.  
 Washington, D.C. 20001-4413

JAN 04 2006

```

<400> 24
agaattaagc ttagtttaaa cggccggccg gcgcgcctta ttataagcct aaggcagctt 60

<210> 25
<211> 32
<212> DNA
<213> Artificial Sequence
<220>
<221> primer_bind
<223> forward primer useful for generation of albumin fusion protein in which
the albumin moiety is N-terminal of the Therapeutic Protein
<220>
<221> misc feature
<222> (18)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (19)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (20)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (21)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (22)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (23)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (24)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (25)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (26)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (27)
<223> n equals a,t,g, or c
<220>

```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,  
Garrett & Dunner, L.L.P.  
901 New York Avenue, N.W.  
Washington, D.C. 20001-4413

JAN 04 2005

<221> misc feature  
 <222> (28)  
 <223> n equals a,t,g, or c  
 <220>  
 <221> misc feature  
 <222> (29)  
 <223> n equals a,t,g, or c  
 <220>  
 <221> misc feature  
 <222> (30)  
 <223> n equals a,t,g, or c  
 <220>  
 <221> misc feature  
 <222> (31)  
 <223> n equals a,t,g, or c  
 <220>  
 <221> misc feature  
 <222> (32)  
 <223> n equals a,t,g, or c

<400> 25  
 aagctgcctt aggcttannn nnnnnnnnnn nn

32

<210> 26  
 <211> 51  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <221> primer\_bind  
 <223> reverse primer useful for generation of albumin fusion protein in which  
 the albumin moiety is N-terminal of the Therapeutic Protein  
 <220>  
 <221> misc feature  
 <222> (37)  
 <223> n equals a,t,g, or c  
 <220>  
 <221> misc feature  
 <222> (38)  
 <223> n equals a,t,g, or c  
 <220>  
 <221> misc feature  
 <222> (39)  
 <223> n equals a,t,g, or c  
 <220>  
 <221> misc feature  
 <222> (40)  
 <223> n equals a,t,g, or c  
 <220>  
 <221> misc feature  
 <222> (41)  
 <223> n equals a,t,g, or c  
 <220>

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,  
 Garrett & Dunner, L.L.P.  
 901 New York Avenue, N.W.  
 Washington, D.C. 20001-4413

JAN 04 2005

```

<221> misc feature
<222> (42)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (43)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (44)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (45)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (46)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (47)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (48)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (49)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (50)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (51)
<223> n equals a,t,g, or c

<400> 26
gcgcgcgttt aaacggccgg ccggcgcgcc ttattannnn nnnnnnnnnn n
51

<210> 27
<211> 33
<212> DNA
<213> Artificial Sequence
<220>
<223> forward primer useful for generation of albumin fusion protein in which
the albumin moiety is c-terminal of the Therapeutic Protein
<220>
<221> misc feature

```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,  
Garrett & Dunner, L.L.P.  
901 New York Avenue, N.W.  
Washington, D.C. 20001-4413

JAN 04 2006

<222> (19)  
<223> n equals a,t,g, or c  
<220>  
<221> misc feature  
<222> (20)  
<223> n equals a,t,g, or c  
<220>  
<221> misc feature  
<222> (21)  
<223> n equals a,t,g, or c  
<220>  
<221> misc feature  
<222> (22)  
<223> n equals a,t,g, or c  
<220>  
<221> misc feature  
<222> (23)  
<223> n equals a,t,g, or c  
<220>  
<221> misc feature  
<222> (24)  
<223> n equals a,t,g, or c  
<220>  
<221> misc feature  
<222> (25)  
<223> n equals a,t,g, or c  
<220>  
<221> misc feature  
<222> (26)  
<223> n equals a,t,g, or c  
<220>  
<221> misc feature  
<222> (27)  
<223> n equals a,t,g, or c  
<220>  
<221> misc feature  
<222> (28)  
<223> n equals a,t,g, or c  
<220>  
<221> misc feature  
<222> (29)  
<223> n equals a,t,g, or c  
<220>  
<221> misc feature  
<222> (30)  
<223> n equals a,t,g, or c  
<220>  
<221> misc feature  
<222> (31)  
<223> n equals a,t,g, or c  
<220>  
<221> misc feature

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,  
Garrett & Dunner, L.L.P.  
901 New York Avenue, N.W.  
Washington, D.C. 20001-4413

JAN 04 2006

<222> (32)  
 <223> n equals a,t,g, or c  
 <220>  
 <221> misc feature  
 <222> (33)  
 <223> n equals a,t,g, or c  
  
 <400> 27  
 aggagcgtcg acaaaagann nnnnnnnnnn nnn

33

<210> 28  
 <211> 52  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <221> primer\_bind  
 <223> reverse primer useful for generation of albumin fusion protein in which  
 the albumin moiety is c-terminal of the Therapeutic Protein  
 <220>  
 <221> misc feature  
 <222> (38)  
 <223> n equals a,t,g, or c  
 <220>  
 <221> misc feature  
 <222> (39)  
 <223> n equals a,t,g, or c  
 <220>  
 <221> misc feature  
 <222> (40)  
 <223> n equals a,t,g, or c  
 <220>  
 <221> misc feature  
 <222> (41)  
 <223> n equals a,t,g, or c  
 <220>  
 <221> misc feature  
 <222> (42)  
 <223> n equals a,t,g, or c  
 <220>  
 <221> misc feature  
 <222> (43)  
 <223> n equals a,t,g, or c  
 <220>  
 <221> misc feature  
 <222> (44)  
 <223> n equals a,t,g, or c  
 <220>  
 <221> misc feature  
 <222> (45)  
 <223> n equals a,t,g, or c  
 <220>  
 <221> misc feature

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,  
 Garrett & Dunner, L.L.P.  
 901 New York Avenue, N.W.  
 Washington, D.C. 20001-4413

JAN 04 2006

```

<222> (46)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (47)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (48)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (49)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (50)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (51)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (52)
<223> n equals a,t,g, or c

<400> 28
ctttaaatcg atgagcaacc tcaactcttgt gtgcacnnnn nnnnnnnnnn nn      52

<210> 29
<211> 24
<212> PRT
<213> Artificial Sequence
<220>
<221> signal
<223> signal peptide of natural human serum albumin protein

<400> 29
Met Lys Trp Val Ser Phe Ile Ser Leu Leu Phe Leu Phe Ser Ser Ala
  1           5           10           15

Tyr Ser Arg Ser Leu Asp Lys Arg
      20

<210> 30
<211> 114
<212> DNA
<213> Artificial Sequence
<220>
<221> primer_bind
<223> forward primer useful for generation of PC4:HSA albumin fusion VECTOR

```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,  
Garrett & Dunner, L.L.P.  
901 New York Avenue, N.W.  
Washington, D.C. 20001-4413

JAN 04 2006

```

<220>
<221> misc_feature
<222> (5)..(10)
<223> BamHI restriction site
<220>
<221> misc_feature
<222> (11)..(16)
<223> Hind III restriction site
<220>
<221> misc_feature
<222> (17)..(27)
<223> Kozak sequence
<220>
<221> misc_feature
<222> (25)..(97)
<223> cds natural signal sequence of human serum albumin
<220>
<221> misc_feature
<222> (75)..(81)
<223> XhoI restriction site
<220>
<221> misc_feature
<222> (98)..(114)
<223> cds first six amino acids of human serum albumin

<400> 30
tcagggatcc aagcttcgc caccatgaag tgggtaacct ttatttcct tctttttctc 60

tttagctcgg cttactcgag ggggtgtgtt cgtcgagatg cacacaagag tgag      114

<210> 31
<211> 43
<212> DNA
<213> Artificial Sequence
<220>
<221> primer_bind
<223> reverse primer useful for generation of PC4:HSA albumin fusion VECTOR
<220>
<221> misc_feature
<222> (6)..(11)
<223> Asp718 restriction site
<220>
<221> misc_feature
<222> (12)..(17)
<223> EcoRI restriction site
<220>
<221> misc_feature
<222> (15)..(17)
<223> reverse complement of stop codon
<220>
<221> misc_feature
<222> (18)..(25)

```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,  
Garrett & Dunner, L.L.P.  
901 New York Avenue, N.W.  
Washington, D.C. 20001-4413

JAN 04 2006

```

<223> AscI restriction site
<220>
<221> misc_feature
<222> (18)..(43)
<223> reverse complement of DNA sequence encoding last 9 amino acids

<400> 31
gcagcggtac cgaattcggc ggccttata agcctaaggc agc 43

<210> 32
<211> 46
<212> DNA
<213> Artificial Sequence
<220>
<221> primer_bind
<223> forward primer useful for inserting Therapeutic protein into pC4:HSA
vector
<220>
<221> misc feature
<222> (29)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (30)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (31)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (32)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (33)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (34)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (35)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (36)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (37)

```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,  
Garrett & Dunner, L.L.P.  
901 New York Avenue, N.W.  
Washington, D.C. 20001-4413

JAN 04 2005

<223> n equals a,t,g, or c  
 <220>  
 <221> misc feature  
 <222> (38)  
 <223> n equals a,t,g, or c  
 <220>  
 <221> misc feature  
 <222> (39)  
 <223> n equals a,t,g, or c  
 <220>  
 <221> misc feature  
 <222> (40)  
 <223> n equals a,t,g, or c  
 <220>  
 <221> misc feature  
 <222> (41)  
 <223> n equals a,t,g, or c  
 <220>  
 <221> misc feature  
 <222> (42)  
 <223> n equals a,t,g, or c  
 <220>  
 <221> misc feature  
 <222> (43)  
 <223> n equals a,t,g, or c  
 <220>  
 <221> misc feature  
 <222> (44)  
 <223> n equals a,t,g, or c  
 <220>  
 <221> misc feature  
 <222> (45)  
 <223> n equals a,t,g, or c  
 <220>  
 <221> misc feature  
 <222> (46)  
 <223> n equals a,t,g, or c

<400> 32  
 ccgccgctcg aggggtgtgt ttcgtcgann nnnnnnnnnn nnnnnn

46

<210> 33  
 <211> 55  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <221> primer\_bind  
 <223> reverse primer useful for inserting Therapeutic protein into pC4:HSA  
 vector  
 <220>  
 <221> misc feature  
 <222> (38)

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,  
 Garrett & Dunner, L.L.P.  
 901 New York Avenue, N.W.  
 Washington, D.C. 20001-4413

JAN 04 2006

<223> n equals a,t,g, or c  
 <220>  
 <221> misc feature  
 <222> (39)  
 <223> n equals a,t,g, or c  
 <220>  
 <221> misc feature  
 <222> (40)  
 <223> n equals a,t,g, or c  
 <220>  
 <221> misc feature  
 <222> (41)  
 <223> n equals a,t,g, or c  
 <220>  
 <221> misc feature  
 <222> (42)  
 <223> n equals a,t,g, or c  
 <220>  
 <221> misc feature  
 <222> (43)  
 <223> n equals a,t,g, or c  
 <220>  
 <221> misc feature  
 <222> (44)  
 <223> n equals a,t,g, or c  
 <220>  
 <221> misc feature  
 <222> (45)  
 <223> n equals a,t,g, or c  
 <220>  
 <221> misc feature  
 <222> (46)  
 <223> n equals a,t,g, or c  
 <220>  
 <221> misc feature  
 <222> (47)  
 <223> n equals a,t,g, or c  
 <220>  
 <221> misc feature  
 <222> (48)  
 <223> n equals a,t,g, or c  
 <220>  
 <221> misc feature  
 <222> (49)  
 <223> n equals a,t,g, or c  
 <220>  
 <221> misc feature  
 <222> (50)  
 <223> n equals a,t,g, or c  
 <220>  
 <221> misc feature  
 <222> (51)

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,  
 Garrett & Dunner, L.L.P.  
 901 New York Avenue, N.W.  
 Washington, D.C. 20001-4413

JAN 04 2006

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (52)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (53)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (54)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (55)

<223> n equals a,t,g, or c

<400> 33

agtcccatcg atgagcaacc tcactcttgt gtgcacnnnn nnnnnnnnnn nnnnn 55

<210> 34

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<221> signal

<223> Stanniocalcin signal peptide

<400> 34

Met Leu Gln Asn Ser Ala Val Leu Leu Leu Leu Val Ile Ser Ala Ser Ala

1

5

10

15

<210> 35

<211> 22

<212> PRT

<213> Artificial Sequence

<220>

<221> signal

<223> Synthetic signal peptide

<400> 35

Met Pro Thr Trp Ala Trp Trp Leu Phe Leu Val Leu Leu Leu Ala Leu

1

5

10

15

Trp Ala Pro Ala Arg Gly

20

<210> 36

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,  
Garrett & Dunner, L.L.P.  
901 New York Avenue, N.W.  
Washington, D.C. 20001-4413

JAN 04 2006

```

<221>primer_bind
<223>Degenerate VH forward primer useful for amplifying human VH domains

<400> 36
caggtgcagc tggcgcagtc tgg                                     23

<210> 37
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate VH forward primer useful for amplifying human VH domains

<400> 37
caggtcaact taagggagtc tgg                                     23

<210> 38
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate VH forward primer useful for amplifying human VH domains

<400> 38
gaggtgcagc tggcgcagtc tgg                                     23

<210> 39
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate VH forward primer useful for amplifying human VH domains

<400> 39
caggtgcagc tgcaggagtc ggg                                     23

<210> 40
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate VH forward primer useful for amplifying human VH domains

<400> 40
gaggtgcagc tggcgcagtc tgc                                     23

<210> 41
<211> 23

```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,  
Garrett & Dunner, L.L.P.  
901 New York Avenue, N.W.  
Washington, D.C. 20001-4413

JAN 04 2006

```

<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate VH forward primer useful for amplifying human VH domains

<400> 41
caggtacagc tgcagcagtc agg                23

<210> 42
<211> 24
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate JH reverse primer useful for amplifying human VH domains

<400> 42
tgaggagacg gtgaccaggg tgcc                24

<210> 43
<211> 24
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate JH reverse primer useful for amplifying human VH domains

<400> 43
tgaagagacg gtgaccattg tccc                24

<210> 44
<211> 24
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate JH reverse primer useful for amplifying human VH domains

<400> 44
tgaggagacg gtgaccaggg ttcc                24

<210> 45
<211> 24
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate JH reverse primer useful for amplifying human VH domains

<400> 45
tgaggagacg gtgaccgtgg tccc                24

```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,  
Garrett & Dunner, L.L.P.  
901 New York Avenue, N.W.  
Washington, D.C. 20001-4413

JAN 04 2006

<210> 46  
 <211> 23  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <221>primer\_bind  
 <223>Degenerate Vkappa forward primer useful for amplifying human VL domains  
  
 <400> 46  
 gacatccaga tgacccagtc tcc 23  
  
 <210> 47  
 <211> 23  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <221>primer\_bind  
 <223>Degenerate Vkappa forward primer useful for amplifying human VL domains  
  
 <400> 47  
 gatgttgtga tgactcagtc tcc 23  
  
 <210> 48  
 <211> 23  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <221>primer\_bind  
 <223>Degenerate Vkappa forward primer useful for amplifying human VL domains  
  
 <400> 48  
 gatattgtga tgactcagtc tcc 23  
  
 <210> 49  
 <211> 23  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <221>primer\_bind  
 <223>Degenerate Vkappa forward primer useful for amplifying human VL domains  
  
 <400> 49  
 gaaattgtgt tgacgcagtc tcc 23  
  
 <210> 50  
 <211> 23  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <221>primer\_bind  
 <223>Degenerate Vkappa forward primer useful for amplifying human VL domains

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,  
 Garrett & Dunner, L.L.P.  
 901 New York Avenue, N.W.  
 Washington, D.C. 20001-4413

JAN 04 2006

<400> 50	
gacatcgtga tgacccagtc tcc	23
<210> 51	
<211> 23	
<212> DNA	
<213> Artificial Sequence	
<220>	
<221>primer_bind	
<223>Degenerate Vkappa forward primer useful for amplifying human VL domains	
<400> 51	
gaaacgacac tcacgcagtc tcc	23
<210> 52	
<211> 23	
<212> DNA	
<213> Artificial Sequence	
<220>	
<221>primer_bind	
<223>Degenerate Vkappa forward primer useful for amplifying human VL domains	
<400> 52	
gaaattgtgc tgactcagtc tcc	23
<210> 53	
<211> 23	
<212> DNA	
<213> Artificial Sequence	
<220>	
<221>primer_bind	
<223>Degenerate Vlambda forward primer useful for amplifying human VL domains	
<400> 53	
cagtctgtgt tgacgcagcc gcc	23
<210> 54	
<211> 23	
<212> DNA	
<213> Artificial Sequence	
<220>	
<221>primer_bind	
<223>Degenerate Vlambda forward primer useful for amplifying human VL domains	
<400> 54	
cagtctgccc tgactcagcc tgc	23
<210> 55	
<211> 23	
<212> DNA	
<213> Artificial Sequence	
<220>	

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,  
Garrett & Dunner, L.L.P.  
901 New York Avenue, N.W.  
Washington, D.C. 20001-4413

JAN 04 2006

```

<221>primer_bind
<223>Degenerate Vlambda forward primer useful for amplifying human VL domains

<400> 55
tcctatgtgc tgactcagcc acc 23

<210> 56
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221>primer_bind
<223>Degenerate Vlambda forward primer useful for amplifying human VL domains

<400> 56
tcttctgagc tgactcagga ccc 23

<210> 57
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221>primer_bind
<223>Degenerate Vlambda forward primer useful for amplifying human VL domains

<400> 57
cacgttatac tgactcaacc gcc 23

<210> 58
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221>primer_bind
<223>Degenerate Vlambda forward primer useful for amplifying human VL domains

<400> 58
caggctgtgc tcaactcagcc gtc 23

<210> 59
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221>primer_bind
<223>Degenerate Vlambda forward primer useful for amplifying human VL domains

<400> 59
aattttatgc tgactcagcc cca 23

```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,  
Garrett & Dunner, L.L.P.  
901 New York Avenue, N.W.  
Washington, D.C. 20001-4413

JAN 04 2006

```

<210> 60
<211> 24
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate Jkappa reverse primer useful for amplifying human VL domains

<400> 60
acgtttgatt tccaccttgg tccc                24

<210> 61
<211> 24
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate Jkappa reverse primer useful for amplifying human VL domains

<400> 61
acgtttgatc tccagcttgg tccc                24

<210> 62
<211> 24
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate Jkappa reverse primer useful for amplifying human VL domains

<400> 62
acgtttgata tccactttgg tccc                24

<210> 63
<211> 24
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate Jkappa reverse primer useful for amplifying human VL domains

<400> 63
acgtttgatc tccaccttgg tccc                24

<210> 64
<211> 24
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate Jkappa reverse primer useful for amplifying human VL domains

```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,  
Garrett & Dunner, L.L.P.  
901 New York Avenue, N.W.  
Washington, D.C. 20001-4413

JAN 04 2005

<400> 64  
 acgtttaatc tccagtcgtg tccc 24  
  
 <210> 65  
 <211> 23  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <221>primer\_bind  
 <223>Degenerate Jlambda reverse primer useful for amplifying human VL domains  
  
 <400> 65  
 cagtctgtgt tgacgcagcc gcc 23  
  
 <210> 66  
 <211> 23  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <221>primer\_bind  
 <223>Degenerate Jlambda reverse primer useful for amplifying human VL domains  
  
 <400> 66  
 cagtctgccc tgactcagcc tgc 23  
  
 <210> 67  
 <211> 23  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <221>primer\_bind  
 <223>Degenerate Jlambda reverse primer useful for amplifying human VL domains  
  
 <400> 67  
 tcctatgtgc tgactcagcc acc 23  
  
 <210> 68  
 <211> 23  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <221>primer\_bind  
 <223>Degenerate Jlambda reverse primer useful for amplifying human VL domains  
  
 <400> 68  
 tcttctgagc tgactcagga ccc 23  
  
 <210> 69  
 <211> 23  
 <212> DNA  
 <213> Artificial Sequence  
 <220>

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,  
 Garrett & Dunner, L.L.P.  
 901 New York Avenue, N.W.  
 Washington, D.C. 20001-4413

JAN 04 2006

```

<221>primer_bind
<223>Degenerate Jlambda reverse primer useful for amplifying human VL domains

<400> 69
cacgttatac tgactcaacc gcc 23

<210> 70
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate Jlambda reverse primer useful for amplifying human VL domains

<400> 70
caggctgtgc tcactcagcc gtc 23

<210> 71
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate Jlambda reverse primer useful for amplifying human VL domains

<400> 71
aattttatgc tgactcagcc cca 23

<210> 72
<211> 15
<212> PRT
<213> Artificial Sequence
<220>
<221>turn
<223>Linker peptide that may be used to join VH and VL domains in an scFv.

<400> 72
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
1 5 10 15

<210> 73
<211> 733
<212> DNA
<213> Homo sapiens

<400> 73
gggatccgga gcccaaactc tctgacaaaa ctacacatg cccaccgtgc ccagcacctg 60
aattcgaggg tgcaccgtca gtcttcctct tcccccaaaa acccaaggac accctcatga 120
tctcccgac tcctgaggtc acatgcgtgg tggtggacgt aagccacgaa gaccctgagg 180

```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,  
Garrett & Dunner, L.L.P.  
901 New York Avenue, N.W.  
Washington, D.C. 20001-4413

JAN 04 2006

```

tcaagttcaa ctggtacgtg gacggcgtgg aggtgcataa tgccaagaca aagccgcggg 240
aggagcagta caacagcacg taccggtggtg tcagcgtcct caccgtcctg caccaggact 300
ggctgaatgg caaggagtac aagtgaagg tctccaacaa agccctccca acccccatcg 360
agaaaacat ctccaaagcc aaagggcagc cccgagaacc acaggtgtac accctgcccc 420
catccccgga tgagctgacc aagaaccagg tcagcctgac ctgcctgggtc aaaggcttct 480
atccaagcga catcgccgtg gagggggaga gcaatgggca gccggagAAC aactacaaga 540
ccacgcctcc cgtgctggac tccgacggct ccttcttctc ctacagcaag ctcaccgtgg 600
acaagagcag gtggcagcag gggaaagtct tctcatgtc cgtgatgcat gaggctctgc 660
acaaccacta cagcagaag agcctctccc tgtctccggg taaatgagtg cgacggccgc 720
gactctagag gat 733

```

<210> 74

<211> 5

<212> PRT

<213> Artificial sequence

<220>

<221> misc\_structure

<223> membrane proximal motif of class 1 cytokine receptors

<220>

<221> misc\_feature

<222> (3)

<223> Xaa equals any

<400> 74

Trp Ser Xaa Trp Ser

1

5

<210> 75

<211> 86

<212> DNA

<213> Artificial Sequence

<220>

<221> primer\_bind

<223> forward primer useful for generation of a synthetic gamma activation site (GAS) containing promoter element

<400> 75

gcgcctcgag atttccccga aatctagatt tccccgaaat gatttccccg aaatgatttc 60

cccgaatat ctgccatctc aattag 86

<210> 76

<211> 27

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,  
Garrett & Dunner, L.L.P.  
901 New York Avenue, N.W.  
Washington, D.C. 20001-4413

JAN 04 2006

<212> DNA  
 <213> Artificial Sequence  
 <220>  
 <221> primer\_bind  
 <223> reverse primer useful for generation of a synthetic gamma activation site (GAS) containing promoter element

<400> 76  
 gcggcaagct ttttgcaaag cctaggc 27

<210> 77  
 <211> 271  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <221> misc\_feature  
 <223> Synthetic GAS-SV40 promoter sequence

<400> 77  
 ctcgagattt ccccgaaatc tagatttccc cgaaatgatt tccccgaaat gatttccccg 60  
 aaatatctgc catctcaatt agtcagcaac catagtccccg cccctaactc cgcccatccc 120  
 gccctaact ccgcccagtt ccgcccattc tccgccccat ggctgactaa ttttttttat 180  
 ttatgcagag gccgaggccg cctcggcctc tgagctattc cagaagtagt gaggaggctt 240  
 ttttgagggc ctaggctttt gcaaaaagct t 271

<210> 78  
 <211> 32  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <221> primer\_bind  
 <223> primer useful for generation of a EGR/SEAP reporter construct

<400> 78  
 gcgctcgagg gatgacagcg atagaacccc gg 32

<210> 79  
 <211> 31  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <221> primer\_bind  
 <223> primer useful for generation of a EGR/SEAP reporter construct

<400> 79  
 gcgaagcttc gcgactcccc ggatccgcct c 31

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,  
 Garrett & Dunner, L.L.P.  
 901 New York Avenue, N.W.  
 Washington, D.C. 20001-4413

JAN 04 2006

<210> 80  
 <211> 12  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <221> misc\_binding  
 <223> NF-KB binding site

<400> 80  
 ggggactttc cc 12

<210> 81  
 <211> 73  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <221> primer\_bind  
 <223> forward primer useful for generation of a vector containing the NF-KB promoter element

<400> 81  
 gcggcctcga ggggactttc ccggggactt tccggggact ttccgggact ttccatcctg 60  
 ccatctcaat tag 73

<210> 82  
 <211> 256  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <221> misc\_feature  
 <223> Synthetic NF-KB/SV40 promoter

<400> 82  
 ctcgagggga ctttcccggg gactttccgg ggactttccg ggactttcca tctgccatct 60  
 caattagtca gcaaccatag tcccggccct aactccgccc atcccgcccc taactccgcc 120  
 cagttccgcc cattctccgc cccatggctg actaattttt tttatttatg cagaggccga 180  
 ggccgcctcg gcctctgagc tattccagaa gtagtgagga ggcttttttg gaggcctagg 240  
 cttttgcaaa aagctt 256

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,  
 Garrett & Dunner, L.L.P.  
 901 New York Avenue, N.W.  
 Washington, D.C. 20001-4413

JAN 04 2006